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The medicinal mushroom Ganoderma lucidum has been reported to be 
effective herbal remedy in traditional medicine for its health promoting properties. 
Studies regarding the bioactivity of Ganoderma lucidum have thrived across 
diverse research areas including cancer, diabetes, immune system, hyperglycemia 
and anti-viral [1-6]. The major chemical components of Ganoderma lucidum that 
are believed to be responsible for these effects include polysaccharides and 
triterpenoids. Compared to polysaccharides, Ganoderma lucidum triterpenoids are 
suggested to have more direct effects in cancer prevention. Both the triterpenoid 
extracts and individual triterpenoids including their derivatives have been 
reported to inhibit cell proliferation and induce cell deaths in a number of 
carcinoma cell models [7]. The exact mechanisms for their chemo-preventative 
properties remain unclear, but it is likely due to the diverse chemical structures of 
Ganoderma lucidum triterpenoids and their derivatives.  
Though there have been extensive studies on Ganoderma lucidum 
triterpenoids, literature is sparse in evaluating the associated bioactivity of other 
components in Ganoderma lucidum such as lipids, proteins and nucleosides. In 
recent years, increasing interests have been addressed in chemical and bioactive 
characterization of the lipid constituents in Ganoderma lucidum. Lipids mixture 
and long chain fatty acids have been found to induce apoptosis in human 
leukemia cells [8;9]. While understanding of the compositions in these extracts 
and bioactivity in other carcinoma cells is still limited.  
Thus, this thesis is focusing on investigating the specific bioactivities of 
Ganoderma lucidum lipids and triterpenoids and their derivatives in three cultured 
human carcinoma cells. The overall results indicated that Ganoderma lucidum 
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triterpenoids and their derivatives were able to inhibit cell proliferations in Caco-2 
human colon carcinoma cells, HeLa human cervical carcinoma cells and Hep G2 
human hepatic carcinoma cells and induce apoptotic cell death in Caco-2 and 
HeLa cells. Triterpenoids with functional groups at C-23 position, less saturation 
in the side chain and higher polarity were suggested to have impaired cytotoxicity 
in these cell lines. The Ganoderma lucidum triterpenoids induced-apoptosis was 
associated with caspase activation, membrane protein externalization and 
cytochrome c release, possibly through transcription activation of p53 and E2F 
and down regulation of nuclear factor kappa-light-chain-enhancer of activated B 
cells (NFκB), Myc and hypoxia-inducible factor (HIF). On the other hand, the 
Ganoderma lucidum lipids were shown to induce differentiation in Caco-2 cells 
with accelerated alkaline phosphatase and lactase activity and this action was 
possibly mediated through activation of c-Jun N-terminal kinases (JNK) and 
extracellular signal-regulated kinases (ERK) signaling and involved an indirect 
activation of protein kinase C (PKC). In addition, reliable and rapid methods for 
separating and characterizing Ganoderma lucidum lipids and triterpenoids and 
their derivatives have been developed. Extraction conditions including extraction 
time, temperatures and solvents were evaluated and optimized to obtain maximum 
yields of Ganoderma lucidum triterpenoids. 
The evidence presented in this thesis supports the hypothesis that 
Ganoderma lucidum lipids, triterpenoids, and their derivatives exhibit strong 
bioactivities in cultured human carcinoma cells. Detailed studies on the possible 
direct targets in the regulation signaling would be required for complete 
elucidation of the specific underlying mechanisms. Additionally, future studies 
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may need to be developed for confirming their pharmacological effects in vivo as 
the potential chemotherapeutic agents against cancers.
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CHAPTER 1 INTRODUCTION 
1.1 Overview of Bioactive Components from Ganoderma lucidum 
Ganoderma lucidum, also known as Lingzhi in Chinese, Reshi in Japanese and 
Youngzhi in Korean, is a medicinal herb traditionally used in ancient Asia to promote 
health and cure various diseases and is first recognized in the west in the 18th century 
[10]. Modern research has revealed that Ganoderma lucidum possesses multiple 
pharmacological activities, including anti-inflammatory, anti-tumorigenic, anti-herpetic, 
anti-virus, anti-ulcerogenic, anti-angiogenic, anti-diabetic, hypoglycemic activity and 
osteoclastogenesis-regulated effects [3;6;11-17]. Ganoderma lucidum has been reported 
to consists of a variety of chemical components with bioactive properties, which include 
polysaccharides, triterpenoids, steroids, fatty acids, proteins, peptides, alkaloids and 
nucleosides [18]. Among these ingredients, polysaccharides and triterpenoids are the two 
most extensively studied components. Structure-activity relationship has been indicated in 
the anti-angiogenesis effects and anti-oxidant capacity in Ganoderma lucidum 
polysaccharides [19;20]. Yet little is known of the correlation between the structures of 
Ganoderma lucidum triterpenoids and their associated bioactivities. The potential 
bioactive lipid components present in Ganoderma lucidum has also been garnering recent 
interest [8;21].  
1.2 Objective of Thesis 
Overall Aim 
The overall objective of this thesis is to develop and optimize methods for extraction, 
isolation, characterization of Ganoderma lucidum triterpenoids and lipids and to assess 




1. To develop crude Ganoderma lucidum extracts and generate fractions that contain 
enriched triterpenoids (Chapter 3) 
2. To assess bioactive response of Caco-2 cells to two Ganoderma lucidum triterpenoids 
enriched fractions (Chapter 3) 
3. To characterize and quantify a Ganoderma lucidum lipid enriched fraction (Chapter 4) 
4. To investigate the induction of differentiation on Caco-2 cells resulted from 
Ganoderma lucidum lipid enriched fraction (Chapter 4) 
5. To model effects of extraction conditions on triterpenoid profiles and develop 
optimized extraction conditions for certain triterpenoids (Chapter 5) 
6. To develop methods for isolation and identification of individual triterpenoids and their 
derivatives (Chapter 5 and 6) 
7. To measure the corresponding anti-proliferative effects of isolated individual 
triterpenoids and their derivatives on Caco-2, HeLa and Hep G2 cells (Chapter 5 and 6) 
8. To quantify the levels of apoptosis induced by triterpenoids and their derivatives and 




CHAPTER 2 LITERATURE REVIEW 
Preface 
Selected portion of Chapter 2 have been published in the following publication 
Ruan, W.; Popovich, D. G. Evidence of bioactivity from Ganoderma lucidum 
triterpenoids in cultured cell models. In Saponins: Properties, Applications and Health 
Benefits, Nova Science Publishers. 2011, 145-156. 
 
2.1 Overview of Triterpenoids from Ganoderma lucidum 
2.1.1 Extraction, Isolation and Identification of Ganoderma lucidum Triterpenoids 
Triterpenoids derived from Ganoderma lucidum are oxygenated tetracyclic 
triterpenoids. The majority of these triterpenoids are ganoderic acids (C30) and lucidenic 
acid (C27). In addition to the two major triterpenoids, ganolucidic acids, ganoderenic 
acids, ganoderiols, ganodermadiol, ganodermatriol, ganodermanondiol, 
ganodermanontriol, lucidumols, ganoderic aldehydes and lucialdehydes are also found in 
Ganoderma lucidum. New triterpenoids are continuously discovered by different research 
groups. For example, 7-O-ethyl ganoderic acid O was newly found from fermented 
mycelia of Ganoderma lucidum by silica gel chromatography [22]. A novel ganoderic 
acid, ganoderic acid FWI was found in a methanolic extract [23]. Additionally, new 
triterpenoid derivatives such as ganofuran B, butyl ganoderate and butyl lucidenate were 
discovered [2;24]. Nevertheless, many more triterpenoids from Ganoderma lucidum 
remain undiscovered and worthwhile to explore. Chemical structures of representative 




Figure 1. Chemical structures of triterpenoids from Ganoderma lucidum # refers to double 
bonds, * represents newly discovered triterpenoids in recent years by different research 
groups. 
 
Due to the complex profile of triterpenoids from Ganoderma lucidum, extraction and 
isolation of triterpenoids from Ganoderma lucidum usually involves multiple steps of 
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separation and purification. Organic solvents such as methanol, ethanol and chloroform 
are commonly used as extraction solvents and various methods of isolation including 
repeated silica gel column chromatography, C18 cartridge, preparative high performance 
liquid chromatography (HPLC), capillary zone electrophoresis and supercritical fluid 
extraction (SFE), has been employed to obtain purified triterpenoid extracts or individual 
triterpenoids [25-29]. However, effects of extraction conditions on recovery yields of 
certain triterpenoids remain unclear.  
Identification of Ganoderma lucidum triterpenoids using thin layer chromatography 
(TLC) has been reported as an economic and simple approach while HPLC coupled with 
UV detector are employed prevalently [29-31]. However, since triterpenoids are not the 
exclusive components absorbed in the detective UV wavelengths and standards for many 
triterpenoids are not commercially available; LC-MS is generally required for accurate 
identification of triterpenoids from Ganoderma lucidum. Electron spray ionization (ESI) 
and atmospheric pressure chemical ionization (APCI) have been used in assisting 
confirmation of the structures of triterpenoids with same molecule weight by examination 
of the fragmentation patterns including the cleavage of A, B, C, D ring, loss of methyl 
radical and fragmentation of side chain [32;33]. Yet there are few reports of such 
fragmentation patterns on triterpenoid derivatives and exact identification may need 
combining analysis of ESI and nuclear magnetic resonance (NMR).    
2.1.2 Bioactivities of Ganoderma lucidum Triterpenoids in Cell Culture 
2.1.2.1 Anti-Inflammatory, Adipogenesis and Osteoclast Differentiation Effect in 
Cultured Cells 
Triterpenoids from Ganoderma lucidum have been reported to exhibit diverse 
bioactivity in variety of cell culture models. Extracts of triterpenoids from Ganoderma 
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lucidum possessed anti-inflammatory effects on lipopolysaccharide (LPS)-stimulated 
macrophages by suppressing secretion of potentially harmful cytokines tumor necrosis 
factor-α (TNF-α) and interleukin-6 (IL-6) [34].  
Butyl ganoderate A and butyl lucidenate N isolated from Ganoderma lucidum were 
demonstrated to inhibit adipogenesis in 3T3-L1 cells by down-regulation of the 
adipogenic transcription factor sterol regulatory element-binding protein -1c and its target 
genes, such as fatty acid synthase (FAS) and acetyl-CoA carboxylase [35]. Another 
triterpenoid T-butyl lucidenate B was also shown to exert adipogenesis inhibitory effect 
by reduction of triglyceride accumulation and suppression of glycerol-3-phosphate 
dehydrogenase (GPDH) activity and gene expressions of peroxisome 
proliferator-activated receptor (PPAR) γ, CCAAT/enhancer-binding proteins (C/EBP) α, 
and sterol regulatory element-binding protein -1c [36]. Recently, a Ganoderma lucidum 
extract containing approximately 10% of ganoderic acid A was reported to promote 
adipocyte differentiation and adiponectin production by activating PPARγ and PPARα 
[37]. Production of adiponectin is associated with an improved metabolic potential, which 
is the adaptive response with increasing oxidative potential and greater ability to use fat 
as a fuel.  
Triterpenoids from Ganoderma lucidum could be beneficial in osteoclastogenesis 
therapeutics. Inhibition of osteoclast differentiation helps in preventing excessive 
osteoclastic bone resorption, which is believed to be responsible for osteopenic diseases 
such as osteoporosis and rheumatoid arthritis. Ganoderic acid DM and ganoderic acid F 
were found to exhibit cytotoxicities and inhibit osteoclast differentiation in RAW264 
mouse leukemic monocyte-macrophage cells. These effects were mediated by 
suppression of c-Fos and the nuclear factor of activated T cells c1 (NFATc1) which 
subsequently suppressed expression of dendritic cell-specific transmembrane protein 
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(DC-STAMP) and reduced osteoclast fusion [38]. Additionally, a structure-activity 
relationship was believed to exist in the inhibitory activity [12].  
2.1.2.2 Chemoprevention 
The most extensively studied of Ganoderma lucidum triterpenoids bioactivity is their 
anti-tumor or chemo-preventative effects. Both triterpenoid extracts from Ganoderma 
lucidum and individual isolated triterpenoids have been reported to inhibit cell growth and 
cause cell deaths in various carcinoma cells. Preliminary research mainly focused on the 
cytotoxic properties of triterpenoids from Ganoderma lucidum on tumor cells. For 
instance, ethanol extracts from Ganoderma lucidum have been studied using human 
cervical carcinoma HeLa cells [39]. Additionally, individual triterpenoids including 
lucidenic acid N, lucidenic acid A, and ganoderic acid E have been showed significant 
cytotoxicity in Hep-G2 and murine P-388 lymphocytic leukemia cells [40]. Recently, a 
possible mechanism of the anti-tumor properties has been partly elucidated. Molecular 
mechanisms involved include multiple programmed cell death such as apoptosis, 
autophagy and senescence and reduce or prevent cellular metastasis. The 
chemo-preventative properties from Ganoderma lucidum triterpenoids are summarized in 
Table 1. 
Table 1. Summary of the type of cell death in specific cell lines using triterpenoids from 
Ganoderma lucidum. 
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2.1.2.2.1 Programmed Cell Death 
Apoptosis 
One of the most commonly studied bioactive properties of natural products is the 
ability to inhibit apoptosis in cancer cell lines. Methanol extracts containing ganoderic 
acids and triterpenoid derivatives were found to induce apoptosis and necrosis in 
transplantable B16 murine melanoma cells, mouse ﬁbrosarcoma L929 cells and rat 
astrocytoma C6 cells. The apoptotic cell death involved was caspase-dependent and 
mediated by up-regulation of tumor suppressor protein p53 and suppression of 
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anti-apoptotic protein B-cell lymphoma -2 (Bcl-2) expression [41]. Another methanol 
extract possibly containing triterpenoids was also indicated to cause apoptosis in 
interleukin 3-dependent lymphoma cells (DA-1) with reduction of expression of 
NFkB-p65 factor and inactivated caspase-3 [42]. Additionally, induction of apoptosis in 
NB4 human leukemia cells was found with treatment of a similar methanol extract 
possibly containing triterpenoids. The corresponding activity involved reductions of p53, 
Akt, Erk level as well as the Bcl2/ Bcl-2-associated X protein (Bax) ratio [43]. 
Triterpenoid enriched extract by ethanol extraction was shown to induce apoptosis in 
platelet-derived growth factor (PDGF)-activated rat hepatic stellate cells (HSC-T6) and it 
was mediated by down-regulation of cyclins D1 and D2, PDGFβR and Akt 
phosphorylation, up-regulation of JNK phosphorylation, and expression of α-SMA [56]. 
Ethanol extracts of triterpenoids from Ganoderma lucidum also induced apoptosis in 
human hepatocarcinoma Hep3B and HepG2 cells [45;46]. However, the underlying 
molecular mechanisms were not elucidated. In addition to hepatocarcinoma cells, ethanol 
extracts exhibited anti-proliferative activities on human breast cancer cells (MCF-7 and 
MDA-MB-231), myeloid leukemia cells (HL-60) and AGS human gastric carcinoma cells 
through induction of apoptosis [45;47]. Induction of apoptosis in AGS human gastric 
carcinoma cells was associated with two distinct pathways including extrinsic plasma 
membrane death receptor-mediated pathway and intrinsic mitochondria-mediated 
pathway which corresponded to inactivation of Akt [47]. More recently, 
a triterpene-enriched extract was found to induce apoptosis in SW620 human colorectal 
carcinoma cells by activating caspase-3, up-regulating p53 and down-regulating Bcl2/Bax 
ratio [48].  
Individual triterpenoid, ganoderic acid Me was reported to induce apoptosis in 
HCT-116 human colon carcinoma cells through mitochondrial mediated pathway. 
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Increased expression of p53 and reduced Bcl-2/Bax ratio were reported [49]. The 
induction of apoptosis was also coupled with reduced mitochondria trans-membrane 
potential, released cytochrome c from mitochondria into the cytosol and increased 
caspase-3 activity. Following a similar mechanism induced by ganoderic acid Me in 
HCT-116cells, a pair of position isomer, ganoderic acid Mf and ganoderic acid S were 
able to trigger apoptotic cell death in HeLa cells. The actions involved decreased 
Bcl-2/Bax ratio, activated caspase-3 and caspase-9, decreased mitochondria membrane 
potential and release of cytochrome c [50].  
Autophagy and Senescence 
Another type of programmed cell death is termed autophagy and it may be 
responsible for part of the cytotoxic properties and mechanisms attribute to the 
chemo-prevention properties of Ganoderma lucidum triterpenoids. Triterpenoids from 
Ganoderm lucidum induced autophagic cell death in HT-29 human colon cancer cells, 
which was associated with formation of autophagic vacuoles, up-regulation expression of 
Beclin-1 and LC-3 protein. These effects were suggested to be mediated by inhibition of 
p38 mitogen-activated protein kinase (MAPK) [57]. 
When programmed cell death is blocked in cells, irreversible cell growth arrest, 
termed senescence has also been reported activated by Ganoderma lucidum. Ganoderiol F 
has been reported to induce senescence in HepG2 cells. The inhibition of DNA synthesis 
was presumably caused by the inhibition of topoisomerases activity and activation of 
EKR and up-regulation of cyclin-dependent kinase inhibitor p16 might contribute to the 
premature senescence induction [52]. 
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2.1.2.2.2 Anti-Invasion and Anti-Metastasis 
In addition to suppressing the growth of existing tumors, preventing invasion and 
metastasis are also important mechanisms for either treatment. Ganoderic acid A and 
ganoderic acid H were shown to exhibit anti-invasive effects on MDA-MB-231 cells [58]. 
These effects were mediated by down-regulation of transcription factors activator protein 
-1 (AP-1) and NF-κB, subsequently suppressed expression of cyclin-dependent kinase 
(Cdk) 4 and secretion of urokinase-type plasminogen activator (uPA), respectively. 
Structure-activity relationship was also suggested. Ganoderic acid T was also 
demonstrated to effectively inhibit tumor metastasis in 95-D human highly metastatic 
lung tumor cells via blocking expression of matrix metalloproteinase (MMP) -2 and 
MMP-9 which could be mediated by inactivation of NF-κB [54]. Lucidenic acids A, B, C 
and N were found to possess anti-invasive activity on phorbol-12-myristate-13-acetate 
(PMA)-induced Hep G2 cells by down regulating MMP-9 activity. Inhibition of ERK1/2 
phosphorylation and reduction of DNA-binding activities of AP-1 and NF-kB were 
reported to be involved in this process [59].  
Triterpenoids from Ganoderma lucidum have been reported to possess diverse 
bioactive properties and perhaps the most convincing evidence for bioactivity is the 
chemo-preventative properties. These triterpenoids may induce activity mediated though 
activation of multiple programmed cell death pathways. However, elucidating a 
structure-activity relationship on specific cancer cell lines using individual isolated 
triterpenoids is still limited. 
2.2 Overview of Lipids from Ganoderma lucidum 
2.2.1 Chemical Characterization of Lipids from Ganoderma lucidum 
Unlike triterpenoids from Ganoderma lucidum, investigations of the lipid 
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components from Ganoderma lucidum are far less. It has been reported that ergosterol 
and its ester were found in Ganoderma lucidum with concentrations ranged from 0.8 to 
1.6 mg/g and ergosteryl esters accounted for 3.6% to 41.9% of the total ergosterol with 
respect to different parts of Ganoderma lucidum [60]. In addition to the sterol component, 
approximately 20 kinds of fatty acids have been identified in Ganoderma lucidum lipid 
extracts so far and the major components include linoleic acid, oleic acid, palmitic acid 
and stearic acid. Contents of these acids varied from 4.97% to 76.74% depending on 
extraction methods and cultivation conditions [61;62]. More recently, two 19-carbon fatty 
acids which are nonadecanoic acid and cis-9-nonadecenoic acid has been isolated and 
identified in a Ganoderma lucidum lipid extract [8]. However, many of the lipid 
components remain unknown, which may need further isolation and identification.  
GC-MS is a well accepted approach for identification of lipids and has been used 
exclusively in identifying fatty acids in Ganoderma lucidum [61-63]. However, the 
inability of GC-MS to retrieve tested samples also limits its application when subsequent 
bioactivities investigations on the single component of the mixture are needed. 
Development of LC-MS methods which can subsequently retrieve and separate a mixture 
of lipid compounds is therefore necessary to aid in the lipids-associated bioactivity 
investigations. 
2.2.2 Bioactivities of Ganoderma lucidum Lipids in Cell Culture 
Despite the limited studies on the lipid composition in Ganoderma lucidum, 
significant bioactivity of Ganoderma lucidum lipids has been reported in cultured human 
carcinoma cells. A lipids extract from Ganoderma lucidum has been reported to be a 
potential immune reaction modulator by regulating hepatic lipid metabolism as the extract 
specifically transactivate the PPARα in HepG2 cells [21]. Ganoderma lucidum lipids 
were also found to induce apoptosis in THP-1human leukemia cells with activation of 
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caspase through JNK1/2 activation and ERK1/2 and Akt inhibition [9]. Another mixture 
containing C-19 fatty acids was reported to inhibit cell proliferation and inducing 
apoptosis in HL-60 cells [8]. However, the exact lipid compositions in most of the 
reported extracts were not stated. The literature is also sparse on effects of Ganoderma 
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As previously mentioned in Chapter 2, triterpenoids extracted or isolated from 
Ganoderma lucidum have been reported to be responsible for many of the pharmaceutical 
activities of Ganoderma lucidum [7]. So far, hundreds of triterpenoids have been found in 
Ganoderma lucidum and many more continued to be discovered [22;64;65]. Two major 
types of triterpenoids in Ganoderma lucidum are ganoderic acids (C30) and lucidenic 
acids (C27) and the total triterpenoid content in Ganoderma lucidum varies from 0.6 to 11 
mg/g dry powder [66;67]. These triterpenoids were reported to influence metabolic states 
including exhibiting anti-diabetic properties and regulating inflammatory pathways in cell 
culture [2;37;68]. Triterpenoids from Ganoderma lucidum also possess significant 
chemo-preventative potential. Ganoderiol F (30 μM) was found to induce senescence in 
Hep-G2 cells [52]. Ganoderic acid Mf and S (0-97.7 μM) were reported to suppress cell 
growth of HeLa cells through apoptotic cell death [50]. Ganoderic acid T (24.20 μM) was 
shown to possess anti-metastasis effect on 95-D cells [54]. Multiple regulating 
mechanisms mediated by triterpenoid from Ganoderma lucidum on different colon 
carcinoma cells were also reported. Ganoderic acid Me was shown to induce apoptosis in 
HCT-116 cells with a LC50 of 36.9 μM [49]. While ganodermanontriol (0-80 μM) 
inhibited cell growth in HT-29 cells through down regulation of β-catenin signaling 
16 
 
which binds to T-cell Factor / Lymphocyte Enhancer binding Factor (Tcf/Lef) and 
increases transcriptional activation of cyclin D1, c-myc and proliferator-activated reporter 
δ [69]. Triterpenoid extracts of Ganoderma lucidum also exhibited cytotoxic effects on 
colon carcinoma cells by distinct molecular mechanisms. A Ganoderma lucidum extract 
containing a mixture of lanostanoid triterpenes (0.25 mg/mL) was found to induce 
autophagic cell death in HT-29 cells, while another triterpenoid enriched extract induced 
apoptosis in SW620 cells at a concentration of 50 μM [48;70]. However, content and 
composition of triterpenoids in these extracts were not reported. The objective herein is to 
use a bioassay-guided approach to identify Ganoderma lucidum fractions that are 
cytotoxic and induce apoptosis in Caco-2 cells. 
3.2 Materials and Methods 
3.2.1 Preparation of Ganoderma lucidum Fractions  
Ganoderma lucidum was purchased locally (slice of Ganoderma lucidum, chizhi, 
origin from China), ground and refluxed with 500 mL 95% ethanol (1:20, w/v) for 3.5 h 
and repeated three times. The extraction was modified based on a refererence extraction 
method [71]. The crude extract was filtered, evaporated and lyophilized for further 
fractionation. A flash column chromatography system (combiflash companion, Teledyne 
Isco, Inc., Lincoln, NE, USA) coupled with a reversed phase C18 column (43 g, 40- 63 
μm particle size) (RediSep Rf, Teledyne Isco, Inc., Lincoln, NE, USA) was employed for 
isolating triterpenoid enriched extracts. Gradient elution with a flow rate of 5 mL/min was 
applied to obtain four fractions. Fraction 1 was eluted with 35 % - 61 % ethanol, fraction 
2 with 61 % - 75 % ethanol, fraction 3 with 75 % - 100 % ethanol and fraction 4 with 100 
% ethanol. Each fraction was concentrated under vacuum and lyophilized. The 
triterpenoid enriched fractions (fraction 2 and 3) described below were dissolved in 
17 
 
culture media and passed through a 0.2 μm filter (Millex GP, Millipore, Billerica, MA, 
USA) for bioactive testing.  
3.2.2 HPLC-ESI-MS Analysis 
A Dionex Ultimate 3000 RSLC system (Dionex Corporation, Sunnyvale, CA, USA) 
coupled with Bruker amaZonX IonTrap Mass Spectrometer (Bruker Daltonics Inc., 
Billerica, MA, USA) was used for LC-MS analysis. For separation and identification, a 
Phenomenex Kinetex reversed phase C-18 column (3.0 mm × 100 mm, 2.6 μm particle 
size) (Phenomenex Inc., Torrance, CA, USA) was used. The flow rate was 0.4 mL/min, 
sample injection volume was 5 μL and detection wavelength was set at 254 nm. The 
mobile phase consisted of 1% acetic acid (A) and acetonitrile (B) and gradient conditions 
were set as followed: for fraction 2, 0 - 35 min, 25% B - 35% B; 35 - 45 min, 35% B; for 
fraction 3, 0 - 35 min, 35% B - 95% B; 35 - 40 min, 95% B - 100% B; 40 - 45 min, 100% 
B. For ESI-MS detection, the capillary voltage was set at -4500 V. Flow rate of dry gas 
was 8.0 L/min and dry temperature was set at 250 ºC. Both positive and negative 
ionization were used and scanning mass spectra focused on m/z range of 70 -1500 m/z. 
For tandem MS, a scheduled precursor list was used to fragment the most abundant 
precursor at specific time points.  
3.2.3 Cell Culture 
Caco-2 cells were purchased from American Type Culture Collection (Manassas, 
VA, USA). The cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
(Caisson Laboratories, Inc., North Logan, UT, USA) and supplemented with 10% fetal 
bovine serum (Hyclone UK Ltd., Cambridge, UK), 100 units/mL of penicillin 
/streptomycin (Gibco, Invitrogen, Burlington, Canada) in a humidified atmosphere of 5% 
CO2 at 37 ºC. Cell were maintained at a concentration between 2 × 10
5 and 1 × 106 
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cells/mL, cells were subcultured every 3 - 4 days by total replacement of media using 
0.25% (w/v) trypsin - 0.53 mM ethylenediaminetetraacetic acid solution (Gibco, 
Invitrogen). Viable cells were assessed by the Guava Flow cytometry using 380 μL of 
ViaCount reagent (Guava Technologies, Inc., Hayward, CA, USA) for every sample (20 
μL) for 5 min and data acquired using CytoSoft software equipped with the ViaCount 
module.  
3.2.4 Cell Viability Assay 
Caco-2 cells were seeded at a concentration of 2 × 104 cells/mL in 96-well plates. 
After 24 h, cells were treated with 100 μL/well either fraction 2 or 3 at concentrations 
between 0.1 and 1 mg/mL for 72 h, which were dissolved with 0.4% dimethyl sulfoxide 
(DMSO) in DMEM. Untreated cells acted as controls. After treatment, the media was 
removed and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
(Sigma, St Louis MO, USA) dissolved in DMEM was added at a concentration of 0.5 
mg/mL. Cells were incubated in the dark for 4 h to allow formation of formazan crystals. 
To solubilize the crystals, 100 μL/well of SDS (10%) in HCl (0.01 N) was added and 
incubated overnight as previous described [72]. The optical density was measured at 
absorbance of 570 nm (sample absorbance) and 650 nm (reference absorbance) by a 
microplate reader (Multiskan Spectrum, Thermo Electron Corporation, Waltham, MA, 
USA). Cell viability was calculated as [(mean sample absorbance – mean reference 
absorbance) / (mean control absorbance – mean reference absorbance)] × 100%. 
3.2.5 Cell Cycle Analysis 
Fraction 2 and 3 were added to Caco-2 cells (2 × 104 cells/mL) in 6-well plates at 
their respective LC50 concentrations obtained from the MTT assay. Cells were incubated 
at 37 ºC in a 5% CO2 humidified incubator for 24, 48 and 72 h. Untreated cells acted as 
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controls at each respective time points. After treatment, non-adherent cells in culture 
media were collected by centrifugation at 2500 g for 5 min. The adherent cells were 
trypsinized for 10 min, mixed with 2 mL media and centrifuged at 500 g for 7 min. Cell 
pellets were further washed with phosphate buffered saline (PBS) twice followed by 
centrifugation to remove PBS. Cell pellets of both non-adherent and adherent cells were 
combined and fixed with 70% ice-cold ethanol overnight at -15 ºC. Fixed cells were 
centrifuged at 500 g for 7 min to remove ethanol and washed with PBS twice. After 
removing PBS by centrifugation, 1 mL of PBS containing propidium iodide (PI, 50 
μg/mL, Sigma) and RNase A (100 units /mL, Applichem Inc., St. Louis, MO, USA) were 
added and incubated in the dark for 30 min at room temperature. Samples were analyzed 
by Guava PCA flow cytometry with CytoSoft software (Guava Technologies Inc.) as 
previous described [73]. 
3.2.6 Caspase Apoptotic Assay 
Cells were seeded in 6-well plates at a cell concentration of 2 × 104 cells/mL. After 
24 h, cells were treated with fraction 3 at the LC50 concentration for 48 h. Untreated cells 
acted as controls. After treatment, non-adherent cells in culture media were collected by 
centrifugation at 2500 g for 5 min. The adherent cells were detached by trypsinization and 
centrifuged at 300 g for 7 min. The cell pellets were combined and washed with PBS 
twice. Cells were suspended in PBS and adjusted to a concentration of 5× 105 cells/mL by 
adding 1× apoptotic wash buffer (Guava Technologies Inc.). Five μL of 20 × 
sulforhodamine - valyl - alanyl - fluoromethyl - ketone (SR-VAD-FMK) reagent was 
added to each sample and incubated for 1 h in the dark at 37 ºC in a 5% CO2 incubator. 
The cells were washed with 1× apoptotic wash buffer twice, centrifuged and suspended in 
100 μL 1× apoptotic wash buffer. After the first staining, a second staining with 5 μL of 
caspase 7-amino-actinomycin D (7-AAD) (Guava Technologies Inc.) was employed to 
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each sample for 10 min at room temperature. The sample was finalized to a 200 μL 
sample volume with 1× apoptotic wash buffer and analyzed on Guava PCA flow 
cytometry. 
3.2.7 Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL) 
Assay 
To allow induction of late apoptotic cells, fraction 3 was added at the LC50 
concentration for 72 h in 6-well plates at a seeding concentration of 1× 104 cells/mL. 
Untreated cells acted as controls. After treatment, non-adherent cells were collected by 
centrifugation at 2500 g for 5 min and adherent cells were harvested by trypsinization and 
centrifuged at 300 g for 7 min. Cell pellets were combined and washed with PBS. After 
removing PBS by centrifugation, cells were fixed with 4% paraformaldehyde at 4 ºC for 
45 min followed by 70% ice-cold ethanol overnight at -15 ºC. Fixed cells were 
centrifuged to remove ethanol and washed with 1 mL of the wash buffer (Guava 
Technologies Inc.) three times. The process of cell staining was conducted according to 
the manufacturer’s instructions. Briefly, cells were treated with 25 μL of the DNA 
Labeling Mix Reagent (Guava Technologies Inc.) for 90 min at 37 ºC followed by 
washing with rinsing buffer and centrifugation. The cells were suspended in 50 μL of the 
Anti-BrdU Staining Mix Reagent (Guava Technologies Inc.) and incubated for 30 min at 
room temperature in the dark. At the end of the process, each sample was diluted with 
150 μL rinsing buffer and acquired by a Guava PCA system flow cytometry. 
3.2.8 Statistical Analysis 
A one-way analysis of variance (ANOVA) with Duncan post hoc comparison of 
means and an independent-samples T test were used. Significance was determined at p < 
0.05 using the SPSS statistical software (v12.0, Chicago, IL, USA). HPLC-ESI-MS 
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analysis was conducted with three replicate in two separate experiments. The MTT assay, 
cell cycle analysis, caspase apoptotic assay and TUNEL assay were determined in three 
separate experiments with three replicate.  
3.3 Results  
3.3.1 Triterpenoid Profiles by HPLC-ESI-MS 
Four fractions separated from flash chromatography had recoveries of 6.32%, 
13.24%, 4.35% and 1.24% for fraction 1, 2, 3 and 4 repectively calculated based on their 
weight of powder after lyophilizaiton. Only fraction 1, 2 and 3 had UV absorption in the 
HPLC analysis while fraction 1 cannot be identified as any known components based on 
HPLC-ESI-MS analysis. Representative HPLC chromatographs of fraction 2 and 3 are 
shown in Figure 2 panels (a) and (b) respectively. Fraction 2 contained 12 major 
triterpenoids, including ganoderic acid I (peak 1), ganoderic acid C2 (peak 2), ganoderic 
acid C6 (peak 3), ganoderic acid G (peak 4), ganoderic acid ζ (peak 5), ganoderic acid B 
(peak 6), ganoderenic acid K (peak 7), ganoderic acid K (peak 8), ganoderic acid A (peak 
9), ganoderic acid H (peak 10), ganoderenic acid D (peak 11) and ganoderic acid D (peak 
12). Fraction 3 consisted of three major compounds and two were identified as ganoderic 
acid DM (peak 19) and ganoderic aldehyde TR (peak 21). Additionally, two other minor 
components were identified as lucidenic acid D1 (peak 15) and ganoderic acid Z (peak 
17). The maximum absorbent wavelengths of tested compounds determined by 
photodiode array detector and fragmentation patterns generated from tandem mass 
spectrometry (MS) in both positive mode and negative mode were utilized for 
identification by comparing fragmentation patterns, retention times and molecular 
weights to published references [24;32;74-79]. Representative MS fragments of 
compounds in fraction 2 and 3 extracts are listed in Table 2. Since the fragmentation 
patterns of compounds corresponding to peak 13, 14, 16, 18 and 20 did not match any 
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published references, these compounds were considered as unknown compounds. They 
were subsequently isolated into individual compounds and identified by NMR analysis as 
ganolucidic acid E (peak 13), lucidumol A (peak 14), ganodermanontriol (peak 16), 
7-oxo-ganoderic acid S (peak 18) and 15-hydroxy-ganoderic acid Z (peak 20) in charpter 
6. Chemical structures of the components identified in fraction 2 and 3 in this charptor are 
illustrated in Figure 3.   
 
Figure 2. Representative HPLC chromatographs of fraction 2 (panel a) and fraction 3 (panel 
b) from Ganoderma lucidum. 1, ganoderic acid I; 2, ganoderic acid C2; 3, ganoderic acid C6; 
4, ganoderic acid G; 5, ganoderic acid ζ; 6, ganoderic acid B; 7, ganoderenic acid K; 8, 
ganoderic acid K; 9, ganoderic acid A; 10, ganoderic acid H; 11, ganoderenic acid D; 12, 
ganoderic acid D; 13*, ganolucidic acid E; 14*, lucidumol A; 15, lucidenic acid D1; 16*, 
ganodermanonotriol; 17, ganoderic acid Z; 18*, 7-oxo-ganoderic acid S; 19, ganoderic acid 
DM; 20*, 15-hydroxy-ganoderic acid Z; 21, ganoderic aldehyde TR.*, compounds were 
identified in chapter 6. 
Table 2. Representative MS fragments of major compounds in Ganoderma lucidum fraction 2 
and 3 extracts. 
Peak 
No.  
Compound  Representative MS fragments  
1  ganoderic acid I  531.0[M-H]-, 513.3[M-H-H2O]
-, 1063.7[2M-H]-  
2  ganoderic acid C2  517.3[M-H]-, 499.3[M-H-H2O]
-, 437.4[M-H-H2O-CO2]
-, 1035.8[2M-H]-  







4  ganoderic acid G  531.3[M-H]-, 513.3[M-H-H2O]
-, 469.3[M-H-H2O-CO2]
-, 1063.8[2M-H]-  
5  ganoderic acid ζ  513.3[M-H]-, 495.3[M-H-H2O]
-, 399.2[M-H-C5H6O3]
-, 1027.8[2M-H]-  
6  ganoderic acid B  515.3[M-H]-, 497.3[M-H-H2O]
-, 453.3[M-H-H2O-CO2]
-, 1031.5[2M-H]-  
7  ganoderenic acid K  571.3[M-H]-, 553.4[M-H-H2O]
-, 1143.7[2M-H]-  
8  ganoderic acid K  573.3[M-H]-, 555.3[M-H-H2O]
-, 513.3[M-H-C2H4O2]
-, 511.3[M-H-H2O-CO2]
-, 1147.7[2M-H]-  
9  ganoderic acid A  515.3[M-H]-, 497.3[M-H-H2O]
-, 479.3[M-H-2H2O]
-, 435.4[M-H-2H2O-CO2]
-, 1031.6[2M-H]-  
10  ganoderic acid H  571.1[M-H]-, 553.3[M-H-H2O]
-, 511.3[M-H-C2H4O2]
-, 1143.7[2M-H]-  
11  ganoderenic acid D  511.3[M-H]-, 493.3[M-H-H2O]
-, 1023.4[2M-H]-  
12  ganoderic acid D  513.3[M-H]-, 495.0[M-H-H2O]
-, 451.3[M-H-H2O-CO2]
-, 1027.5[2M-H]-  
13  unknown  485.6[M+H]+, 483.3[M-H]-  
14 unknown 473.4[M+H]+, 471.6[M-H]- 
   15  lucidenic acid D1  471.4[M+H]+, 469.5[M-H]-, 939.6[2M-H]-, 353.4[M-C6H12O2-H]
-  
16 unknown 531.8[M-H]- 
17  ganoderic acid Z  457.4[M+H]+, 439.3[M+H-H2O]
+, 383.5[M+H-H2O-C3H4O]
+  
18 unknown 471.3[M+H]+ 
19  ganoderic acid DM  469.4[M+H]+, 937.3[2M+H]+, 466.9[M-H]-, 935.6[2M-H]-, 326.3[M- C8H13O2-H]
-  
20 unknown 469.3[M+H]+ 







Figure 3. Chemical structures of representative compounds in Ganoderma lucidum fraction 2 
and 3 extracts, numbers under compound refers to the Table 2 column 1. 
 
3.3.2 MTT Cytotoxicity Assay and Cell Cycle Distribution  
Representative dose-response relationships of fraction 2 and 3 extracts on Caco-2 
cell viability are shown in Figure 4. The LC50 values were determined by plotting cell 
viabilities against log concentrations (from 0.1 to 1mg/mL, graph not shown) and linear 
equations of y = − 60.236 x + 33.076 (R2 = 0.9515) (fraction 2) and y = − 97.085 x + 
5.655 (R2 = 0.9238) (fraction 3) were determined. The LC50 value of fraction 2 and 3 
extracts on Caco-2 cells was calculated to be 0.528 ± 0.078 and 0.348 ± 0.032 mg/mL 
respectively. The representative dose-response relationship of fraction 1 extract on 
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Caco-2 cell viability is shown in Apendix 2 and the ones of crude extract and fraction 4 
are discussed in chapter 4. 
 
Figure 4. Cell viability of fraction 2 and 3 treated Caco-2 cells for 72h and assessed using the 
MTT assay. Values are expressed as mean ± SD (percentage of untreated control cells) of 
three separate experiments with three replicate. 
 
The corresponding cell cycle distributions of fraction 2 and 3 treatment at their 
respective LC50 concentration for 24, 48 and 72 h are shown in Table 3. Treatment of 
fraction 2 and 3 both significantly (p < 0.05) induced cell cycle arrest at G2/M phase for 
all the time periods and maximum accumulation (6.43 % for fraction 2 and 9.76 % for 
fraction 3) for 48 h treatment. The results also indicated a significant (p < 0.05) reduction 
of cell percentage at G0/G1 phase for all the time periods on Caco-2 cells treated by both 
fractions and maximum reduction of 10.94% for fraction 2 and 21.34% for fraction 3 
were observed after 72 h. Conversely, cells treated with fraction 3 were found to be 
significantly (p < 0.05) increased (6.46% and 15.95%) at the sub-G1 phase for 48 and 72 
h, indicating DNA fragmentation, while fraction 2 did not show differences in this phase 




Table 3. Cell cycle analysis of Caco-2 cells with treatment of fraction 2 and 3 at their 
respective LC50 concentration obtained by MTT assay. Values are expressed as mean ± SD. 
An asterisk represents significant differences (p < 0.05) in the same phases within the same 
period compared to control values. 
 
Sub-G1  G0/G1  S  G2/M  
Fraction 2  
24 hr  










48 hr  
control  3.23±0.67  45.27±0.70  16.27±3.70  34.87±2.38  







72 hr  










Fraction 3  
24 hr  
control  2.30±0.36  38.40±3.14  20.37±1.36  38.53±1.94  







48 hr  










72 hr  











3.3.3 Detection of Apoptosis by Caspase Apoptotic and TUNEL Assays  
To confirm the induction of apoptosis by fraction 3, caspase apoptotic assay was  
conducted. The different stages of apoptosis induced by treatment of fraction 3 extract on 
Caco-2 cells are shown in Figure 5. As described previously [80], mid-apoptotic cells are 
stained positively with SR-VAD-FMK but not with the membrane integrity indicator 
7-AAD. The late apoptotic cells are stained positively by both SR-VAD-FMK and 
7-AAD while viable cells are not stained with neither. Dead cells would not be stained by 
SR-VAD-FMK but would be positively stained with 7-AAD. Compared to the control, 
treatment of fraction 3 for 48 h significantly (p < 0.05) increased mid-apoptotic cells 
(6.27%) and late-apoptotic cells (10.59%). Correspondingly, viable cells from fraction 3 
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treatment significantly (p < 0.05) decreased 15.67% compared to the control value. The 
percentage of dead cells did not show significant differences between treatment and 
control. 
 
Figure 5. Representative flow cytometry analysis of caspase activity of fraction 3 treated 
Caco-2 cells. Caco-2 cells were treated by fraction 3 extract at the LC50 concentration 
determined by the MTT analysis for 48 h (panel b). Untreated cells acted as controls (panel a). 
Quadrant analysis of control cells indicated 74.84 ± 2.94% viable cells compared to 59.17 ± 
5.45%* with fraction 3 treatment. Dead cells were 14.37 ± 3.72% of control and 13.11 ± 
0.58% of fraction 3 treatment. Mid-apoptotic cells were 5.46 ± 1.15% of control and 11.73 ± 
2.05%* of fraction 3. Late apoptosis cells were 5.44 ± 1.38% of control and 16.03 ± 2.45%* 
of fraction 3. SR-VAD-FMK is labeled on the x-axis, and 7-AAD is labeled on the y-axis. An 
asterisk represents a significant difference (p < 0.05) compared to the corresponding control 
values. 
 
To quantify the apoptotic fragment induced by treatment of fraction 3, TUNEL assay 
was used and analyzed by flow cytometry. The DNA fragments generated by the 
induction of apoptosis were immuno-stained positively by a fluorescence dye FITC. 
Results of this assay are shown in Figure 6. Fraction 3 treatment for 72 h resulted in a 
significant (p < 0.05) increase in apoptotic cells (27.94%) and a corresponding decrease 




Figure 6. TUNEL apoptotic analysis of fraction 3 extract-treated Caco-2 cells for 72 h at the 
LC50 concentration. Data are expressed as mean ± SD of three replicate with three separate 
experiments. Analysis of control cells (a) resulted in 97.97 ± 0.68% non-apoptotic, and 2.03 ± 
0.68% were apoptotic. Fraction 3 treated cells (b) were found to have 70.03 ± 3.03%* 
non-apoptotic, and 29.97 ± 3.03%* apoptotic. An asterisk represents a significant difference 
(p < 0.05) compared to the corresponding control values. 
 
3.4 Discussions 
Two distinct triterpenoid containing fractions were prepared from Ganoderma 
lucidum based on polarity. Both extracts were found to be cytotoxic and were dependent 
on the concentration of the extracts. LC50 of fraction 2 was 0.528 ± 0.078 mg/mL and 
fraction 3 was 0.348 ± 0.032 mg/mL. Fraction 2 contained ganoderic acids ζ, A, B, C2, 
C6, D, G, H, I, K and ganoderenic acids D and K and were more polar compared to 
fraction 3 which contained lucidenic acid D1, ganoderic acid Z, ganoderic acid DM and 
ganoderic aldehyde TR. The cytotoxic properties reported here are consistent with results 
obtained in other cell lines such as human hepatoma Huh-7 cells and MCF-7 cells that 
have reported LC50 values of 0.45 and 0.22 mg/mL respectively [45;81]. Similar 
compounds found in ginseng have been reported to possess a structure function effect in 
reducing cell viability in cultured cancer cells and cytotoxicity generally increases as the 
polarity decreases [82]. 
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Both fractions caused a cell cycle arrest at G2/M phase with maximum increased cell 
percentages of 6.43 % and 9.76 % for fraction 2 and 3 treatment respectively. The G2/M 
arrest is consistent with observations in other cell lines including Huh-7 cells, HL-60 cells 
and RPMI8226 cells [45;83]. Further investigation of specific cyclins and 
cyclin-dependent kinases may help in understanding the mediation of this cell cycle arrest. 
Additionally, fraction 3 but not fraction 2 treatment suggested a significant accumulation 
of cells in the sub-G1 phase of the cell cycle, which indicated DNA fragmentation and 
apoptosis. The induction of apoptosis by fraction 3 treatment was further confirmed and 
quantified by caspase apoptotic and TUNEL assays. The positive results shown in 
SR-VAD-FMK staining in the caspase apoptotic assay also suggested that activation of 
the caspase cascade was involved in the induction of apoptosis in Caco-2 cells treated 
with fraction 3. Further studies are required to determine the specific caspase involved. 
Similar cell death mechanism was reported in another colon carcinoma cell line with 
triterpenoid extract treatment [48]. However, induction of apoptosis was not the only 
reported cell death mechanism by triterpenoids from Ganoderma lucidum and multiple 
cell death mechanisms were proposed. A triterpenoid extract (0.25 mg/mL) was reported 
to induce autophagic cell death in HT-29 cells with increasing levels of autophagic 
markers Beclin-1 and microtubule-associated protein 1 light chain 3, by the inhibition of 
p38 mitogen-activated protein kinase [84]. Since the compositions and content of 
triterpenoids in the reported extracts were not specified, the molecular mechanism 
responsible for the cytotoxic effects of triterpenoids from Ganoderma lucidum is likely 
cell specific and dependent on chemical structures. This is evident by the different 
bioactive response obtained from fraction 2, which contained triterpenoids that all have 
an oxyl or hydroxyl group at position C-23, and fraction 3, which contained identified 
triterpenoids that did not have any functional groups at C-23. Both extracts exhibited 
cytotoxicity but varied in apoptotic response. The side chain variability of triterpenoids is 
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likely to be responsible for these distinct cell cyto-activities. A structure-activity 
relationship study in multiple cell lines will add to the understanding of behavior of 
triterpenoids from Ganoderma lucidum in cancer cell models. Interestingly, an unknown 
compound possibly a triterpenoid was found to be one of the major components in 
fraction 3. Further isolation and purification are underway to identify the exact chemical 
structure of this unknown compound. The quantification of triterpenoids in the extract is 
challenging due to the unavailability of commercial standards and variability in maximum 
absorbance wavelengths of triterpenoids. Nevertheless, this chapter shows the induction 
of apoptosis from specific set of triterpenoids in cultured human colon carcinoma Caco-2 
cells. The findings may contribute to the understanding of the diverse pharmaceutical 
properties of Ganoderma lucidum triterpenoids as chemo-preventative agents that is 
dependent on the chemical structure.   
3.5 Conclusions 
An ethanolic extraction of Ganoderma lucidum, a medicinal mushroom, was 
fractioned into four extracts by flash chromatography. Only fraction 2 and 3 contained 
triterpenoids. Fraction 2 was less polar and contained ganoderic acids ζ, A, B, C2, C6, D, 
G, H, I, K and ganoderenic acids D and K, all with presence of oxyl or hydroxyl groups at 
position C23. Fraction 3 contained ganoderic acid DM, ganoderic aldehyde TR and an 
unknown compound. None of identified compounds has functional groups at C23. Both 
fraction 2 and 3 inhibited Caco-2 cells in a dose dependent manner. The LC50s of 
fraction 2 and 3 were 0.528 ± 0.078 and 0.348 ± 0.032 mg/mL. A significant 
accumulation of sub - G1 cells (18.77 ± 4.37 %) was found with fraction 3 but not with 
fraction 2. TUNEL assay resulted in 29.97 ± 3.03 % apoptotic cells and caspase apoptotic 
assay showed 11.73 ± 2.05 % mid-apoptotic cells and 16.03 ± 2.45 % late apoptotic cells. 
The caspase apoptotic assay indicated an involvement of caspase enzyme family 
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mediation. Two fractions were cytotoxic. Fraction 2 caused a G2/M arrest while fraction 





CHAPTER 4 GANODERMA LUCIDUM EXTRACT AND ITS LIPID ENRICHED 
FRACTION INDUCE DIFFERENTIATION IN CACO-2 HUMAN COLON 
CARCINOMA CELLS 
Preface 
Selected portion of Chapter 4 are ready to be submitted as: 
Ruan, W.; Popovich, D. G. Ganoderma lucidum extract and its lipid enriched fraction 
induce differentiation in Caco-2 human colon carcinoma cells. xxx. 2013. 
 
4.1 Introduction 
Colorectal cancer is the third most common cancer with approximately 1.2 million 
new cases diagnosed each year and the fourth leading cause of cancer deaths with more 
than 600 000 deaths each year worldwide [85]. Studies on colorectal cancer and its 
prevention and treatment by traditional medicine have garnered increasing interests 
nowadays. Ganoderma lucidum, as one of the most extensively used and pharmaceutical 
effective medicinal herbs, has been reported to inhibit cell growth in colon carcinoma 
cells through inducing apoptotic and autophagic cell deaths, most of which is due to its 
triterpenoid contents [86;87]. However, effects of Ganoderma lucidum lipids on colon 
carcinoma cells remains unclear, though a lipid extract of Ganoderma lucidum has been 
reported to regulate hepatic lipid metabolism in human carcinoma hepatic cells (HepG2) 
and its C-19 fatty acids to induce apoptosis in human leukemia cells (HL-60) [8;21]. 
Lipids such as fatty acids have been strongly suggested as adjunctive 
chemotherapeutic agents for colon cancer due to their diverse anti-neoplastic properties to 
promote apoptosis [88]. For instant, Docosahexaenoic acid (DHA) has been reported to 
reduce cell viability and promote apoptosis possibly through altering gene expression and 
activating caspase and poly ADP-ribose polymerase (PARP) in colon carcinoma cells 
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[89;90]. These bioactivities in colon carcinoma cells vary with respect to a different lipid 
composition. Unlike DHA, short chain fatty acids such as butyrate, mostly reduced the 
cell viability by promoting colorectal cell differentiation. Though the exact mechanisms 
remain to be elucidated, it is believed that this action required activation of JNK and PKC 
pathways and was probably through inhibiting histone deacetylase which subsequently 
allowed transcription factors to activate differentiation-related genes [91-93]. Induction of 
differentiation could be of clinical significance to regain normal cell control from 
malignant phenotype as differentiated cells may serve as transition stage from 
proliferation to cell death with limited proliferative capacity and life span [94;95]. 
Therefore, based on the above understanding, we believed that Ganoderma lucidum lipids 
might possess a similar adjunctive colorectal chemotherapeutic potential by influencing 
the cell differentiation and apoptosis. Hence, this chaptor was to investigate the effects of 
a lipid-enriched fraction of Ganoderma lucidum extract on viability and differentiation on 
human colon carcinoma Caco-2 cells and possible signaling involvement.  
4.2 Materials and Methods 
4.2.1 Extracts Preparation 
Dried Ganoderma lucidum was purchased locally (slice of Ganoderma lucidum, 
chizhi, origin from China), grounded and extracted with 95% ethanol thrice. The alcohol 
was evaporated under vacuum and the extract was lyophilized. The extract was then 
fractioned by a flash column chromatography system (Combiflash companion) with a 
reversed phase C18 column (43 g, 40- 63 μm particle size) (RediSep Rf, Teledyne Isco, 
Inc.) to give four fractions as described in Chapter 3 [96]. Fraction 1 was eluted with 35 
% - 61 % ethanol, fraction 2 with 61 % - 75 % ethanol, fraction 3 with 75 % - 100 % 
ethanol and fraction 4 with 100 % ethanol. Each solvent mixture was evaporated under 
vacuum and lyophilized.  
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4.2.2 Determination of Lipid Composition 
The non-esterified fatty acid content was quantified by a colorimetric enzyme assay 
with a commercial kit (NEFA C, Wako Pure Chemical Industries, Ltd. Osaka, Japan). 
The crude extract and the four fractions were dispersed into deionized water by sonication 
to a concentration of 1 mg/mL and 50 µL was used for each sample according to the 
manufacture’s instruction. 
A Dionex Ultimate 3000 RSLC system (Dionex Corporation) coupled with Bruker 
amaZonX IonTrap Mass Spectrometer (Bruker Daltonics Inc.) was used to determine the 
specific lipid composition of fraction 4. A Phenomenex Kinetex reversed phase C-18 
column (3.0 mm × 100 mm, 2.6 μm particle size) (Phenomenex Inc.) was used. The 
mobile phase consisted of 1% acetic acid (A) and acetonitrile (B). The flow rate was set 
at 0.4 mL/min and gradient conditions were set as followed: 0 - 35 min, 35% B - 95% B; 
35 - 40 min, 95% B - 100% B; 40 - 55 min, 100% B. For ESI-MS/MS detection, a 
capillary voltage of -4500 V, a dry gas flow rate of 8.0 L/min and a dry temperature of 
250 ºC were set. The scanning mass spectra range from 70 m/z to 1200 m/z was used 
under both positive and negative ionization. Auto MS/MS was applied so that two of the 
most abundant precursor ions were fragmented at each time point with a fragment 
amplification power of 2.5 V. The standard solution of oleic acid from the NEFA C kit 
was used as an external standard. Fraction 4 was dissolved in 70% acetonitrile in a 
concentration of 0.6 mg/mL and 3 μL was injected for analysis. 
The lipid composition of fraction 4 further went through NMR analysis for structure 
confirmation. A Bruker AMX 500 NMR spectrometer (Bruker BioSpin GmbH, 
Rheinstetten, Germany) was used. Fraction 4 (5 mg) was dissolved in deuterated 
chloroform (CDCl3) and distortionless enhancement of polarization transfer (DEPT) 
13C 
NMR analysis was applied. 
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4.2.3 Cell Culture 
Caco-2 cells derived from American Type Culture Collection (Manassas, VA, USA). 
The cells were cultured as stated in chapter 3. Viable cells were counted using a 
hemocytometer by staining cells with 0.04% trypan blue exclusion dye (MP Biomedicals, 
Solon, OH, USA). All sample treatments were dissolved with 0.4% DMSO in DMEM 
before tests. 
4.2.4 MTT Assay 
Caco-2 cells were seeded in 96-well plates (2 × 104 cells/mL) for 24 h. Cells were 
treated with either the crude extract or fraction 4 at concentrations between 0.1 and 1 
mg/mL for 72 h. A further set of cells were cultured for 4 days to begin differentiation, 
and then treated with the crude extract or fraction 4 at concentration between 0.1 and 1 
mg/mL for 48 h. Untreated cells acted as controls. A 0.5 mg/mL MTT solution (Sigma) 
was added after treatment and incubated in the dark for 4 h. SDS (10%) in HCl (0.01 N) 
was added and incubated overnight to dissolve the crystals. The optical density was 
measured at absorbance of 570 nm with a reference wavelength of 650 nm by a 
microplate reader (Multiskan Spectrum, Thermo Electron Corporation, Waltham, MA, 
USA). Cell viability was calculated as [(mean sample absorbance – mean reference 
absorbance) / (mean control absorbance – mean reference absorbance)] × 100% [97]. 
4.2.5 Cell Cycle Analysis 
Cells were seeded in 6-well plates at a concentration of 2 × 104 cells/mL. The crude 
extract at its LC50 concentration determined by MTT assay (described below) and 
fraction 4 at a concentration of 0.5 mg/mL were tested for 24, 48 and 72 h respectively. 
Untreated cells acted as controls at each time points. Cell pellets were collected, fixed and 
stained as previous described in chapter 3 [98]. 
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4.2.6 Alkaline Phosphatase Activity 
Caco-2 cells were seeded in 12-well plates (2 × 104 cells/mL) for 4 days before 
treatment to allow cells to start differentiation. Cells were then incubated with 0.5 mg/mL 
of either the crude extract or fraction 4 for 48 h. After treatment, the cells were 
homogenized with 2% triton X-100- 1×- tris - buffer solution (triton X-100, Eastman 
Kodak Company, Rochester, NY, USA ; 20× tis-buffer tablet, Sigma) and centrifuged at 
2500 g for 10 min at 4 ºC to obtain cell lysate. 100 μL/well of 1× p-nitrophenyl phosphate 
solution (20 × p- nitrophenyl phosphate tablets, Sigma) was added into 100μL/well cell 
lysates for 30 min at room temperature in the dark to allow the development of the yellow 
soluble end product p-nitrophenol. The enzyme activity was measured by determining the 
amount of p-nitrophenol spectrophotometrically at a wavelength of 405 nm using a 
microplate reader (Multiskan Spectrum). One unit of enzyme activity is defined as the 
activity that hydrolyzes 1 μmol p- nitrophenyl phosphate per min at 37°C. The total 
protein content of each sample was determined by Bradford’s method using a commercial 
kit (Bio-rad protein assay dye reagent, Bio-Rad Laboratories Inc. Hercules, CA, USA) 
[99]. 
4.2.7 Protein Kinase Inhibitors 
To determine the possible involvement of signal transduction pathway during 
differentiation, three protein kinase inhibitors of MEK/ERK (U0126, 10 μM, Sigma), 
JNK (SP600125(10 μM, Sigma) and PKC (Ro-31-8220, 10 nM, Cayman chemical, Ann 
Arbor, MI, USA), all of which have been reported to mediate Caco-2 differentiation, were 




4.2.8 Lactase Activity 
Cells were seeded, cultured and treated as described above (alkaline phosphatase 
activity). Cells were harvested and homogenized with 2% triton X-100 solution (Eastman 
Kodak Company) at 4ºC and pelleted by centrifuge at 2500 g for 10 min. The enzyme 
activity was determined by its catalytic hydrolysis of 
o-nitrophenyl-β-D-galactopyranoside (ONPG) substrate to generate a yellow end product. 
The reaction was carried out in 10 μL 0.1% bovine serum albumin (BSA), 50 μL 10 mM 
ONPG - 0.1M citrate - phosphate solution (pH 4.3, Sigma), 40 μL cell lysates at 37ºC for 
30 min and stopped by adding 100 μL 1 M Na2CO3. The absorbance of the end product 
was measured at 410 nm using a microplate reader (Multiskan Spectrum). One unit of 
enzyme activity is defined as the activity that hydrolyzes 1 μmol ONPG per min at 37°C. 
The total protein content of each sample was determined by Bradford’s method with the 
commercial kit (Bio-rad protein assay dye reagent) [99]. 
4.2.9 Statistical Analysis 
The data were analyzed using the SPSS statistical software (v12.0, Chicago, IL, 
USA) by one-way ANOVA with Duncan post hoc comparison of means and 
independent-T-test. Significance was determined at p < 0.05. All results were expressed 
as means ± SD and each experiment was determined in three separate experiments with 
three replicate. 
4.3 Results  
4.3.1 Lipids Composition in Ganoderma lucidum Extracts 
The amount of non-esterified fatty acids (Figure 7) in each of the extracts and 
fractions were 0.078 ± 0.013 (crude extract), 0.049 ± 0.013 (fraction 1), 0.063 ± 0.013 
(fraction 2), 0.113 ± 0.013 (fraction 2) and 0.350 ± 0.033 (fraction 4) mEq/L oleic acid 
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for every milligram of the extracts. Fraction 4 accumulated approximately 4.5 times 
non-esterified fatty acids compared to the crude extract.  
 
Figure 7. Non-esterified fatty acid content of Ganoderma lucidum extracts. Values are 
expressed as mean ± SD. 
 
The lipid composition of fraction 4 was further analyzed by LC-MS/MS and NMR. 
Results are shown in Table 4. The NMR spectrum was included in Apendix 4. A total of 
15 compounds were found in fraction 4 including saturated and unsaturated fatty acids, 
hydroxyl fatty acids, sterol derivatives, phospholipids and some non-identified 
compounds. The identified fatty acids in fraction 4 include palmitoleic acid, linoleic acid, 
palmitic acid, oleic acid and stearic acid, which have been confirmed by matching the 13C 
NMR data with representative literatures [102]. The MS data shows that the fatty acids 
tend to form dimmers and lose one molecule of H2O during ionization. Hydroxyl fatty 
acids such as methyl hydroxy-oxo-octanoate, hydroxy-hexadecenoic acid, 
dihydroxy-hydroperoxy-octadecenoic acid, hydroxy-heptadecatrienoic acid and 
hydroxy-heptadecadienoic acid were also found in fraction 4 which is evidenced by the 















































chemical shifts from the NMR spectra such as 13C DEPT        at 70.5 (CHOH), 73.2 
(CHOH), 40.8(CH2CHOH), 36.9(CHOHCH2). The other compounds were believed to be 
sterol derivatives with representative chemical shifts of 70.5(CHOH), 12.1(CH3), 
116.3(CH), 119.6(CH), 16.3(CH3), 21.1(CH3), 135.5(CH), 17.6(CH3), 19.7(CH3), 
19.9(CH3) ppm in 
13C DEPT spectra and phospholipids, identified as phophatidylcholine 









Compound  Representative MS fragments  Chemical shift in 13C DEPT NMR spectra (ppm)  
fatty acids  




, 238.2, 220.3, 165.2, 
136.7, 93.3  29.1(C6),22.7(C7),29.0(C8),  







27.2(C14), 29.3(C15),31.9(C16),22.6(C17),14.1(C18)  
28.7  palmitic acid  257.4[M+2-H]-, 512.6[2M]- ,245.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                 34.2(C2),24.7(C3),29.2-29.7(C4-C13),31.9(C14), 
22.7(C15),14.1 (C16)  







22.6(C17),14.1 (C18)  




 , 148.6  34.2(C2), 24.8(C3),29.2-29.7(C4-C15), 
31.9(C16),22.7(C17),14.1 (C18)  








70.5 (CHOH), 73.2 (CHOH), 
40.8(CH2CHOH),36.9(CHOHCH2)  
4.5  hydroxy- 





9.9  unknown  319.0[M+H]+, 301.0, 283.1, 271.1, 253.3, 204.9,108.8  
11.1  unknown  313.0[M+H]
+
, 295.0, 277.1, 260.1, 249.8, 234.2, 
204.1, 134.7,120.8  
11.8  unknown  333.0[M+H]+, 315.0,307.7, 297.1, 285.1,279.1, 226.3  
12.5  unknown  331.0[M+H]+, 313.1, 295.0, 263.5  
13.7  dihydroxy-hydropero
xy-octadecenoic acid  347.0[M+H]
+
, 329.0, 311.0, 294.0, 264.2, 213.4  
21.9  hydroxy-heptadecatri





 ,264.1 ,246.1, 190.3, 
176.4, 162.4,148.6,122.8,111.1,99.1,87.2  
25.5  hydroxy-heptadecadi





 ,266.1, 248.2, 192.3, 
178.4, 164.6,150.7,122.8,97.1  
sterol derivatives  




34.5  unknown  531.5[M+H]+,427.2, 413.7,391.8  
39.5  unknown  587.6[M+H]+, 448.7, 285.8  
phospholipids  
40.9      phosphatidylcholine  817.6[M-H]-, 754.8,256.7, 282.8  70.2,70.5 (CH sn2),54.6(N(CH3)3)  
    
24.3  fatty ester  257.2[M+H]+,168.4,131.7,104.2  
 




4.3.2 Cytotoxicity of the Extracts and Their Induction of G2/M Arrest 
The effects of the crude extract and fraction 4 treatments on Caco-2 cell viability are 
shown in Figure 8. The crude extract inhibits the cell growth of Caco-2 cells in a dose 
dependent manner when exposed before cell confluency (24 h after seeding) with an 
LC50 of 0.336 ± 0.071 mg/mL. The LC 50 was determined by the linear equation of y = 
− 50.599 x + 25.93 (R2 = 0.9267) obtained by plotting cell viability against log 
concentrations (graph not shown). However, when treated with the crude extract after cell 
confluency (4 days after seeding), cells are resistant to the cytotoxic effects of crude 
extract with cell viability of 63.28 ± 7.81% at a concentration of 1 mg/mL compared to 
untreated control cells. Fraction 4 showed little effects on cell growth, the LC50 could not 
be established up to a tested concentration of 1 mg/mL and showing a 63.46 ± 5.51% and 
70.61 ± 1.82% viability for undifferentiated and confluent cells respectively. 
 
Figure 8. Cell viability of the crude extract and fraction 4 treated Caco-2 cells by MTT assay. 
Values are expressed as mean ± SD (percentage of untreated control cells). Crude 72 h and 
fraction 4 72 h cells represent cells that were seeded for 24 h and treated for 72 h; Crude 4D 

























crude 4D 48h 
fraction 4 72h 
fraction 4 4D 48h 
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The cell cycle analysis is summarized in Table 5. Both the crude extract and fraction 
4 caused a minor G2/M arrest in cell cycle distribution with 4.78% and 7.25% increase 
for the crude extract and 6.56% and 5.30 % increase for fraction 4 after 48 and 72 h 
treatments respectively. However, no significant accumulation was observed in sub-G1, 
which indicated that neither of the treatment induced DNA fragment in Caco-2 cells. 
Table 5. Cell cycle distribution of Caco-2 cells for treatments of crude extract at the LC50 
concentration from MTT assay and fraction 4 with a concentration of 0.5 mg/ml. Values are 
expressed as mean ± SD. An asterisk represents significant differences (p < 0.05) in the same 
phases within the same period compared to control values. 
 
Sub-G1 G0/G1 S G2/M 
Crude  
24 hr  
control  3.06±0.89  38.76±1.91  20.84±1.82  36.48±1.89  
sample  2.63±0.46  33.47±1.52
*
  20.60±1.97  41.63±1.84
*
  
48 hr  
control  2.72±0.48  45.14±1.56  18.96±1.63  30.29±0.83  







72 hr  
control  3.28±0.91  49.17±1.71  19.27±1.64  28.11±1.73  
sample  3.16±0.45  41.43±2.78
*
  20.01±2.42  35.36±2.43
*
  
Fraction 4  
24 hr  
control  3.25±0.37  47.23±3.77  16.90±1.84  30.60±1.11  
sample  2.47±1.21
*
  45.76±2.14  16.33±2.17  35.33±5.52
*
  
48 hr  
control  1.55±0.19  42.33±3.55  17.80±2.86  38.30±1.13  







72 hr  
control  1.58±0.44  46.04±1.04  15.84±1.77  36.53±1.25  




4.3.3 Induction of Differentiation in Caco-2 Cells by Ganoderma lucidum Extracts  
The effects of the crude extract and fraction 4 on cell differentiation were 
determined by measuring the activities of two differentiation enzyme markers, alkaline 
phosphatase and lactase. Both the crude extract and fraction 4 are able to increase the 
activity of alkaline phosphatase and lactase compared to the control (Figure 9). The 
alkaline phosphatase activities significantly (p < 0.05) increased 129% for both the crude 
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extract and 189% for fraction 4 treatment compared to untreated control cell. The lactase 
activities increased significantly (p < 0.05) both for treatments of the crude extract (32%) 
and fraction 4 (113%). 
 
Figure 9. Alkaline phosphatase (left panel) and lactase activities (right panel) in Caco-2 cells 
with treatment of Ganoderma lucidum extracts. Values are expressed as mean ± SD. An 
asterisk represents significant differences (p < 0.05) compared to control values. 
 
4.3.4 Effects of JNK, ERK and PKC Pathway on Alkaline Phosphatase Activity 
Effects of JNK, MEK/ERK and PKC inhibitor on alkaline phosphatase activitiy are 
shown in Table 6. Confluent Caco-2 cells treated with one of three different protein 
kinase inhibitors did not show any significant (p > 0.05) differences in alkaline 
phosphatase compared to control cells without addition of inhibitors. The addition of the 
selective JNK inhibitor SP600125 failed to significantly (p > 0.05) activate the alkaline 
phosphatase activity by treatments of the crude extract and fraction 4, as shown in Table 
6. The relative alkaline phosphatase activity reduced 28% and 87% for treatments of the 
crude extract and fraction 4 respectively after adding SP600125 compared to treatments 
without inhibitor (e.g. ratio of alkaline phosphatase from treatments to control− ratio of 
alkaline phosphatase from treatments with inhibitors to control with inhibitors). Similarly, 
the MEK/ERK-1/2 inhibitor U0126 was able to block the stimulation of alkaline 
































































































relative enzyme activity of 25% (crude extract) and 84% (fraction 4) compared to 
treatments without inhibitor. With addition of the PKC inhibitor Ro31- 8220, the 
stimulated alkaline phosphatase activity by the crude extract treatment was attenuated 
significantly (p < 0.05) by 21% of relative activity compared to treatment without 
inhibitor. While treatment of fraction 4 still significantly (p < 0.05) stimulated alkaline 
phosphatase activity (6.88%) compared to control cells with addition of inhibitor in which 
PKC pathway was blocked by Ro31- 8220. However, the enzyme level was also 
significantly (p < 0.05) reduced (75%) compared to treatment of fraction 4 without PKC 
inhibitor. 
Table 6. Effects of JNK inhibitor SP600125, MEK/ERK inhibitor U0126, PKC inhibitor 
Ro31-8220 and Ganoderma lucidum extracts on alkaline phosphatase activities. Inhibitors 
were added 30 min prior Ganoderma lucidum extracts treatments. Values are expressed as 
mean ± SD. An asterisk represents significant differences (p < 0.05) compared to values of 
untreated cells with inhibitors alone. 
 







Untreated cells + inhibitor 54.04±3.47 46.08±4.30 48.53±4.73 
Crude extract + inhibitor 56.16±3.04 46.38±4.63 52.23±4.06 
Fraction 4 + inhibitor 56.95±6.50 46.83±4.00 55.41±5.10* 
 
4.4 Discussions 
In this chapter, a crude extract and a lipid containing fraction were prepared from 
Ganoderma lucidum. The crude extracted contained a known class of cytotoxic 
triterpenoids that we previously reported in charptor 3 to induce apoptotic cell death in 
Caco-2 colon carcinoma cells [103]. We anticipated a reduction in cell viability and an 
arrest of the cell cycle in Caco-2 cells using a crude extract which contained triterpenoids. 
These apparent cytotoxic effects were diminished once the cells reached confluency and 
treated with the crude extract. Utilizing flash chromatograph four fractions were created 
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by elution with different solvent ratios. Each fraction was separately tested for viability as 
reported in chapter 3. Fraction 4 did not have any effect on cell growth or apoptosis but 
changed the morphology of Caco-2 cells which appeared similar to Caco-2 differentiation. 
We reported herein that fraction 4 contained 4.5 times the non-esterified fatty acid content 
compared to the crude extract and had no measureable triterpenoid content. It was noticed 
that the non-estrified fatty acid content in all extracts was relatively low and below 1 
mEq/L per milligram, which could be due to the low solubility of fatty acids in aqueous 
solusion tested. LC-MS and NMR analysis showed that fraction 4 contained long chain 
saturated and unsaturated fatty acids, hydroxyl fatty acids, sterol derivatives and 
phospholipids. The saturated and unsaturated fatty acid profile has been confirmed by MS 
and NMR analysis and consistent to those reported in Ganoderma lucidum extracts 
[8;104]. Part of the hydroxyl fatty acids and phospholipids were identified while some of 
the sterol derivatives remain unidentified. 
Ganoderma lucidum has been reported to possess multiple pharmaceutical functions 
in chemoprevention as stated in chapter 2 [7;45;52;54]. Treatments using the crude 
extract and fraction 4 both significantly (p < 0.05) increased enzymes activities of 
alkaline phosphatase and lactase, which are the two well accepted markers of colon 
epithelial cell differentiation [93;105;106]. Moreover, fraction 4 increased alkaline 
phosphatase activity 60% and lactase activity 81% more than the crude extract under the 
same concentration (0.5 mg/mL). Therefore, the induction of Caco-2 differentiation is 
stronger for the lipid concentrated fraction of Ganoderma lucidum. Similarly, dietary 
polyunsaturated fatty acids have been reported to the influence breast cancer progression 
in MCF-7 human breast cancer cells and induction of differentiation served as the main 
pathway for the growth inhibitory effects [107]. Regulation of the balance between 
proliferation and differentiation was thought to be important in the development of 
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neoplastic transformation of colonic epithelium [108]. Cells undergo differentiation were 
thought to lose the capability of proliferation and have shorter life span, which serve as an 
effective elimination process for damaged cells to avoid neoplastic transformation [76]. 
The use of non-cytotoxic agents including differentiation agents to treat colon cancer has 
been suggested to help restore normal growth control in carcinoma cells [94]. It has also 
been reported that induction of differentiation was associated with suppression of 
malignant phenotype in colon carcinoma [109;110]. Thus, induction of differentiation by 
Ganoderma lucidum extracts suggests that lipid component may play a role in the 
regulation of differentiation of cultured colonic cells. 
Short chain fatty acids, produced by colonic fermentation, such as butyrate, induced 
colon epithelial differentiation and apoptosis [93]. However, the effects of other lipids on 
colon epithelial differentiation have not been adequately reported in the literature. Unlike 
the short chain fatty acids, the lipids enriched fraction (fraction 4) from Ganoderma 
lucidum neither exhibited cytotoxicity to Caco-2 cells nor induced apoptosis even at a 
high concentration (1 mg/mL). Although the crude extract inhibited cell growth in 
undifferentiated Caco-2 cells, the inhibitory effects diminished after cells reaching 
confluency. This could be a result of rapid metabolism of toxic substance in the extract 
when cells undergo differentiation after reaching confluency [111].  
Regulation of the cell cycle has been reported in colonic epithelial cells 
differentiation and sodium butyrate induced differentiation was thought to involve  
acetylcholinesterase mediated G2/M cell cycle arrest [112]. Cell cycle arrest at G1/S or 
G2/M phases was also believed to correlate with differentiation in Caco-2 cells [113]. A 
G1 arrest was associated with Caco-2/15 cells differentiation [114]. In our study, a G2/M 
cell cycle arrest was observed from both treatments. Fraction 4 increased the cells in 
maximum at the G2/M phase of 7.25% at 48 h while the crude extract showed an increase 
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of 4.78%. The crude extract showed a maximum increase of 6.56% at 72 h compared to 
5.30 % for fraction 4. The different responses of cell cycle arrest for the crude extract and 
fraction 4 may due to the triterpenoid components in the crude extract while Fraction 4 
does not contain any measurable triterpenoids. Triterpenoid rich fraction has been 
reported to cause a G2/M arrest in Caco-2 cells [115]. It is likely that the lipid component 
of fraction is arresting the cell in a different manner than triterpenoids. Similarly, alkaline 
phosphatase and lactase activities were much greater from treatment with fraction 4 at 48 
h compared to the crude extract in confluent cells. However, whether the cell cycle arrest 
play a role in Ganoderma lucidum induced- Caco-2 differentiation is not yet clear and 
need further study.  
Multiple signal transduction pathways have been reported to be responsible for 
mediation of differentiation process in Caco-2 cells. The effects of the addition of three 
protein kinase inhibitors were examined. Stimulation of alkaline phosphatase activity 
during differentiation was inhibited by adding specific inhibitors of JNK (SP600125), 
MEK/ERK (U0126) and PKC (Ro-31-8220). Alkaline phosphatase activity did not 
increase by treatment with either the crude or fraction 4 combined with the inhibitors of 
JNK and MEK/ERK pathways, the enzymatic levels were unchanged compared to 
untreated cell plus those two inhibitors. Therefore alkaline phosphatase activity was 
completely inhibited by JNK and MEK/ERK inhibitors, which suggested these pathways 
were involved in the Ganoderma lucidum induced differentiation reported herein. 
Activation of JNK has been reported to contribute to the spontaneous differentiation of 
Caco-2 and sodium butyrate induced-differentiation [93;101]. Activation of JNK was also 
reported to correlated to differentiation induced by 1,25-Dihydroxyvitamin D3 , which 
was a potential chemo-preventive agent for colon cancer [116]. However, in spontaneous 
differentiating Caco-2 cells, MEK/ERK was reported to be inhibited [101]. This is 
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contrary to our finding that MEK/ERK was activated in Ganoderma lucidum induced 
differentiation. The MEK/ERK inhibitor U0126 used in this study has been reported to 
have the potential to antagonize AP-1 by noncompetitive inhibition, making it potential 
inhibitor of AP-1 [117]. The inhibition of activator protein-1 rather than ERK is very 
likely to result in suppression of differentiation and reduced the Ganoderma lucidum 
stimulate-alkaline phosphatase activity. It is plausible that activator protein -1 could also 
be involved Ganoderma lucidum induced-differentiation. Stimulation of the AP-1 was 
found to be associated with 1,25-Dihydroxyvitamin D3 induced- differentiation in Caco-2 
cells [116].  
The crude extract combined with the PKC inhibitor Ro-31-8220 also resulted in a 
complete inhibition of alkaline phosphatase activity, which was evident by a similar level 
of alkaline phosphatase activity compared to untreated cell plus Ro-31-8220. However, 
fraction 4 combined with the PKC inhibitor resulted in a 6.88% increase in activity, 
indicating a lack of full inhibition of alkaline phosphatase activity from PKC inhibitor 
combined with fraction 4 treatment. Therefore, PKC may play a role in the observed 
differentiation but its activation is probably indirectly affected by Ganoderma lucidum. 
Differentiation induced by sodium butyrate and 1,25-Dihydroxyvitamin D3 were also 
reported to be mediated through activation of PKC in Caco-2 cells [93;116].  
4.5 Conclusions  
An ethanol extract and its lipid fraction from Ganoderma lucidum were found to be 
non-cyctotoxic and both induce differentiation in Caco-2 cells with an increase in alkaline 
phosphatase and lactase activity compared to untreated control cells. The differentiation 
induced by Ganoderma lucidum lipids was possibly mediated through activation of JNK 
and ERK pathways. The lipid composition of Ganoderma lucidum induced differentiation 
in Caco-2 and these effects differed from those of short chain fatty acids.   
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CHAPTER 5 EXTRACTION OPTIMIZATION AND ISOLATION OF 
TRITERPENOIDS FROM GANODERMA LUCIDUM AND THEIR 
CYTOTOXICITIES TO CULTURED HUMAN CARCINOMA CELLS 
Preface 
Selected portion of Chapter 5 are ready to be submitted as: 
Ruan, W.; Lim H.H.A.; Lau G.H.; Popovich, D. G. Extraction optimization and isolation 
of triterpenoids from Ganoderma lucidum and their cytotoxicities to cultured human 
carcinoma cells. xxx. 2013. 
 
5.1 Introduction 
As stated in chapter 2, Ganoderma lucidum is a popular medicinal mushroom used 
as a folk remedy in Asia since ancient time due to its diverse health-promoting properties 
[118;119]. Of special interest is the reported chemo-preventative properties of both the 
polysaccharides and triterpenoids isolated from Ganoderma lucidum [7;119]. In chapter 3, 
two triterpenoid extracts of Ganoderma lucidum (fraction 2 and 3) inhibited cell growth 
in Caco-2 human colon carcinoma cells and one of them with less polarity (fraction 3) 
were able to induce apoptotic cell death [120]. 
Extraction conditions can alter the biochemical profiles of extracts, which 
subsequently influence their bioactive potential. A maximum extraction efficiency of 
target components can be obtained by optimization of the extraction conditions. Response 
surface methodology (RSM) is a well-accepted approach for optimization extractions and 
this method requires fewer experimental trials to evaluate influence of multiple 
parameters such as extraction time, extraction temperature and solvent ratio and their 
interactions [121;122]. It has been reported that the extraction efficiency of 
polysaccharides from Ganoderma lucidum can increase from 42% to 75% using RSM 
guided ultrasound-assisted extraction [123]. However, the effects of extraction conditions 
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on extraction efficiency of triterpenoids from Ganoderma lucidum have not been reported. 
The objective of this chapter is to evaluate and optimize the extraction conditions for 
Ganoderma lucidum triterpenoids, isolate individual triterpenoids and investigate their 
bioactivities in three cultured human cancer cell lines. 
5.2 Materials and Methods 
5.2.1 Extraction Process 
Approximately 2 g of Ganoderma lucidum powder purchased locally (slice of 
Ganoderma lucidum, chizhi, origin from China) was weighted and immersed into 30 mL 
of extraction solvent. The solvent composition, extraction time and extraction temperature 
were varied according to the experimental design (see below). After the extraction, 
samples were filtered under vacuum and solvent was evaporated. The aqueous solution of 
each sample was then lyophilized, weighted and stored at -20 ºC until further analysis. 
Yields of total extract and ganoderic acid H was used as indexes of extraction efficiency 
and calculated as follow: 
                                           
                     
        
 
Yield of ganoderic acid H (  ) (             
                   
        
  
   Where   is the accurate weight of the Ganoderma lucidum powder used for 
extraction,   is the weight of total extract powder after lyophilization.    represents the 
equivalent ganoderic acid H concentration of the total extract in 1 g substance powder 
after lyophilization and   is the ganoderic acid H concentration per gram extract powder 
obtained from the HPLC analysis. 
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5.2.2 Experimental Design 
The Box–Behnken factorial design (BBD Design Expert software, Trial Version 8.0, 
Stat Ease Inc., Minneapolis, MN, USA) was applied to determine the experimental 
conditions which combined three independent variables including extraction time (  ), 
percentage of ethanol in water (  ) and extraction temperature(  ). The range for each 
variable was selected based on a preliminary experiment. The design consisted of 15 
experiments (Table 7) with three replicates at center points for an experimental error sum 
of squares evaluation and all experiments were conducted in randomized order. Data were 
analyzed by a quadratic polynomial model, which expresses the response as a function of 
the independent variables as follow: 
               
 
   
 
   
  
           
   
  
Where   is the response measured,   ,   ,     and     represent the regression 
coefficients of intercept, linearity, quadrate and interaction respectively.    and   are the 
levels of independent variables. 
5.2.3 Determination of Triterpenoids by HPLC 
Analytical HPLC was conducted on a Waters (Milford, MA, USA) 2695 Separation 
system coupled with Waters 2996 Photodiode Array (PDA) detector. A reverse phase 
Agilent Prep C-18 Scalar column (4.6 mm × 250 mm, 10 μm particle size) (Agilent 
Technologies Inc., Santa Clara, CA, USA) was used with a total flow rate of 1 mg/mL. 
The mobile phase consisted of 1% acetic acid (A) and acetonitrile (B). Gradient 
conditions were applied as followed: 0 - 5 min, 5% B - 35% B; 5 - 25 min, 35% - 45% B; 
25 - 35 min, 45% B - 60% B; 35 - 45 min, 60% B - 75% B; 45 - 50 min, 75% B - 95% B; 
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50 - 60 min, 95% B - 100% B; 60 - 70 min, 100% B. The detection wavelength was set at 
254 nm. 
An external standard of ganoderic acid H (Planta Analytica, Irvine, CA, USA) with 
five concentrations ranged from 10 to 100 µg /mL was used for relative quantification. 
Linearity of the calibration curve was determined by plotting concentrations against peak 
areas. 
    Each sample extracted using the BBD model was dissolved in 50% methanol to 
make 1 mg/mL solution and filtered through 0.45 μm filter (Millex GP, Millipore, 
Billerica, MA, USA) and stored at 4 ºC before use. 10 µL of sample was injected for 
HPLC analysis and the component concentrations in samples were calculated using the 
linear equation of the standard curve.    
5.2.4 Isolation of Individual Triterpenoid  
Crude extraction was carried out under the optimal condition obtained from RSM. 
The crude extract was further separated into four fractions using flash chromatography as 
described in chapter 3 [124]. The triterpenoid-enriched fraction (fraction 2) was separated 
by semi-preparative HPLC using a Waters system (Milford, MA, USA) with Waters 515 
HPLC pump, Waters 717 plus autosampler and Waters 2996 PDA detector. A Warers 
XTerra Prep RP-18 column (7.8 mm × 100 mm, 5 μm particle size) (Milford, MA, USA) 
was loaded and a flow rate of 2 ml/min was applied. A mobile phase of deionized water 
(A) and acetonitrile (B) was used with a gradient elution of 35% B at 0 -7 min, 35 - 40% 
B at 7 - 8 min and 40 - 44% B at 8 - 15 min. Samples were prepared in 50% ethanol with 
a concentration of 10 mg/mL and 200 μL was injected for each isolation. A total of 23 
fractions were collected according to the UV absorbance and each fraction was 
evaporated under vacuum to remove solvents and lyophilized. 
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5.2.5 ESI-MS Detection and NMR Determination 
A Bruker amaZonX IonTrap Mass Spectrometer (Bruker Daltonics Inc., Billerica, 
MA, USA) was used for molecular weight determination. The ESI-MS conditions were 
set as follows: dry gas flow rate at 8.0 mL/min, capillary voltage at 4.5 kV, end plate 
offset at -500 V, capillary temperature at 250 oC, flow rate at 0.2 mL/min and injection 
volume of 5 μL. Both positive and negative ionization were used and scanning mass 
spectra was ranged from 70 to 2000 m/z.  
Samples (2-3 mg) were dissolved in 600 μL deuterated chloroform for NMR 
analysis, which was conducted on the Bruker AC300 or AMX500 MHz Nuclear 
Magnetic Resonance Spectrometers (Bruker BioSpin GmbH, Rheinstetten, Germany). 1H, 
13C and DEPT 13C NMR spectra were measured and chemical shifts were expressed in 
terms of δ (ppm).   
5.2.6 Cell Culture 
The Hep G2 cells, Caco-2 cells and HeLa cells derived from American Type Culture 
Collection (Manassas, VA, USA). Cells were cultured in DMEM (Caisson Laboratories, 
Inc.) with supplement of 10% fetal bovine serum (Hyclone UK Ltd.) and 100 units/mL of 
penicillin /streptomycin (Gibco, Invitrogen). The cells were maintained at a concentration 
between 2 × 105 and 1 × 106 cells/mL and subcultured every 3 - 4 days using 0.25% (w/v) 
trypsin - 0.53 mM ethylenediaminetetraacetic acid solution (Gibco, Invitrogen) for a total 
replacement of media. Viable cells were assessed by staining cells with 0.04% trypan 
blue exclusion dye (MP Biomedicals) and counted in a hemocytometer. 
5.2.7 MTT Assay 
Cytotoxicity of Ganoderma lucidum was evaluated by MTT assay. A seeding 
concentration of 2.0 × 104, 2.5 × 104 and 1.5 × 104 cells/mL for Caco-2, Hep G2 and 
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HeLa cells respectively were used in 96-well plates. Cells were allowed to attached for 24 
h and treated with each individual triterpenoid (described below) at concentrations 
between 0.1 and 0.7 mg/mL for 72 h. Untreated cells acted as controls. Cell viability was 
measured as previously described in chapter 3 [125]. 
5.2.8 Statistical Analysis 
The data from RSM were analyzed using Design Expert software (Trial Version 8.0, 
Stat Ease Inc., Minneapolis, MN, USA) by F-test and ANOVA. Significance was 
determined at p < 0.05. Results of the MTT assay were expressed as means ± SD. 
ESI-MS detection and MTT assay were conducted in three separate experiments with 
three replicate. 
5.3 Results and Discussions 
5.3.1 Optimization of Extraction Conditions using RSM 
The representative HPLC profile of crude extraction of Ganoderma lucidum is 
shown in Figure 10(a). To quantify the relative concentrations of the extracts, a standard 
calibration curve of ganoderic acid H is obtained by plotting peak areas against 
concentrations and linear equations of y = 6000000 x – 10414 (R2 = 0.9991) is 
determined (graph not shown). The yields of ganoderic acid H      and total extract 
     from all Ganoderma lucidum extractions are determined and shown in Table 7 in 
terms of equivalent ganoderic acid H content per gram powder of Ganoderma lucidum. 
The quadratic polynomial model is simulated based on the experimental data and 
equations of yields of total substance and ganoderic acid H with linear, square and 
interaction coefficients are shown as follow: 
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Figure 10. (a) Representative HPLC chromatograph of Ganoderma lucidum extract under 
one exraction condition with BBD. Ganoderic acid H was calibrated using an external 
standard. (b) HPLC profile of triterpenoid enriched fraction (fraction 2) separated from 
Ganoderma lucidum extract with optimal extraction condition by semi-preparative HPLC 
isolation. Peak numbers refer to the collected fractions. 8, ganoderic acid I; 12, ganoderic acid 
G; 14, ganoderic acid B; 17, ganoderic acid A; 18, ganoderic acid H; 20, ganoderenic acid D; 
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21, ganoderic acid D. (c) Chemical structures of identified triterpenoids from Ganoderma 
lucidum triterpenoid enriched fraction (fraction 2).  
 











Yields (mg/g powder) 
Total extract Ganoderic acid H 







1 2.0 (-1) 100.0 (1) 50.0 (0) 9.057 8.818 1.57 1.54 
2 2.0 (-1) 50.0 (0) 25.0 (-1) 7.265 7.249 1.26 1.22 
3 4.0 (0) 50.0 (0) 50.0 (0) 9.187 8.821 1.48 1.48 
4 4.0 (0) 100.0 (1) 25.0 (-1) 4.937 5.191 0.99 1.06 
5 6.0 (1) 50.0 (0) 75.0 (1) 9.950 9.963 1.43 1.47 
6 4.0 (0) 50.0 (0) 50.0 (0) 8.316 8.821 1.50 1.48 
7 6.0 (1) 100.0 (1) 50.0 (0) 13.226 13.324 2.09 2.03 
8 4.0 (0) 50.0 (0) 50.0 (0) 8.960 8.821 1.46 1.48 
9 6.0 (1) 50.0 (0) 25.0 (-1) 10.157 9.804 1.57 1.55 
10 6.0 (1) 0.00 (-1) 50.0 (0) 9.751 9.989 1.20 1.23 
11 2.0 (-1) 50.0 (0) 75.0 (1) 8.265 8.618 1.51 1.53 
12 4.0 (0) 0.0 (-1) 25.0 (-1) 7.473 7.587 1.11 1.09 
13 2.0 (-1) 0.0 (-1) 50.0 (0) 10.694 10.595 1.40 1.46 
14 4.0 (0) 100.0 (1) 75.0 (1) 9.245 9.130 1.62 1.64 
15 4.0 (0) 0.0 (-1) 75.0 (1) 5.430 5.175 0.80 0.73 
* refers to mg ganoderic acid H equivalents/g powder. 
 
The significance of each coefficient are determined by the F-value and p-value as 
listed in Table 8. Since a greater F -value and smaller p-value indicated a more 
significant variable affecting the extraction [126], the most significant factors influencing 
the total extract were the linear term of extraction time (  ), interaction of extraction time 
and ethanol ratio (    ), interaction of ethanol ratio and extraction temperature 
(    ) ,the quadratic terms of extraction time (  
 ) and extraction temperature (   
 ). The 
most significant factors that affected the yield of ganoderic acid H included the linear 
terms of extraction time (  ) and ethanol ratio (  ), interaction of extraction time and 
58 
 
ethanol ratio (    ), interaction of extraction time and ethanol ratio (    ), interaction of 
ethanol ratio and extraction temperature (    ), the quadratic terms of extraction time 
(  
 ), ethanol ratio (  
 ) and extraction temperature (  
 ). 
Table 8. Regression coefficients of predicted quadratic polynomial models for the yields of 
total extract and ganoderic acid H.   refers to extraction time;   refers to the ethanol ratio; 
  refers to the extraction temperature. 
Source 
















c acid H 
X1 7.61 0.037 1 7.61 0.037 40.2 8.33 0.0014 0.0344 
X2 1.21 0.39 1 1.21 0.39 6.42 88.62 0.0523 0.0002 
X3 1.17 0.024 1 1.17 0.024 6.17 5.43 0.0556 0.0672 
X1 X2 6.53 0.13 1 6.53 0.13 34.52 29.54 0.002 0.0029 
X1 X3 0.37 0.039 1 0.37 0.039 1.93 8.81 0.2233 0.0312 
X2 X3 10.08 0.22 1 10.08 0.22 53.28 49.42 0.0008 0.0009 
X1
2 14.76 0.15 1 14.76 0.15 77.99 33.05 0.0003 0.0022 
X2
2 0.071 0.049 1 0.071 0.049 0.37 11.2 0.5672 0.0204 
X3
2 13.49 0.2 1 13.49 0.2 71.28 46.72 0.0004 0.001 
Model 57.64 1.26 9 6.4 0.14 33.85 31.92 0.0006 0.0007 
Pure 
Error 













ANOVA for the fitted quadratic polynomial models for the extraction are shown in 
Table 9. The coefficient of determination (R2) are 0.9839 and 0.9829 for the response of 
total triterpenoids and ganoderic acid H respectively, and large R2 is indicative that the 
models adequately represent the experimental data [127]. Thus, the predicted values 
(Table 7) of the amount of total extract and ganoderic acid H obtained from the 
regression equations were achieved and were similar to experimental values.   
 
Table 9. ANOVA for the fitted quadratic polynomial model of extraction of total extract and 




Total extract Ganoderic acid H 
Mean 8.79 1.4 
Std. Dev. 0.44 0.066 
R-Squared 0.9839 0.9829 
Adj R-Squared 0.9548 0.9521 
C.V. % 4.95 4.73 
 
The 3-D response surface plots of yields of total extract and ganoderic acid H was 
obtained by plotting the response against any two variables while the third variable was 
fixed constant at its respective zero level and is shown in Figure 11. When the extraction 
was conducted at a medium extraction temperature (50oC, Figure 11 (a) and (d)), high 
ethanol concentration (100% ethanol) system with long extraction time (6 h) resulted in a 
maximum yield of both total extract and ganoderic acid H. The influence of ethanol 
concentrations in long time extraction (6 h) and effects of extraction time on the yields of 
total extract and ganoderic acid H were also similar. However, medium extraction time (4 
h) seemed to have more negative effects on yield of total extract amount than that of 
ganoderic acids H. In addition, in a short extraction time (2 h), total extract amount 
inversely correlated to the ethanol concentration while the yield of ganoderic acid H 
increased with an accelerated ethanol concentration. When experiments were conducted 
in a solvent system with 50% ethanol (Figure 11 (b) and (e)), higher yields of both total 
extract and ganoderic acid H were observed in a medium extraction temperature with 
either short or long extraction time. Medium extraction time seemed to reduce the yields 
of both total extract and ganoderic acid H. Compared to the yield of ganoderic acid H, 
yield of total extract was more sensitive to the change of extraction time and temperate 
evidenced by more changeful curves. When 4 h extractions were conducted (Figure 2 (c) 
and (f)), extraction temperatures exhibited similar effects on the yields of total extract and 
ganoderic acid H. The yields of both total extract and ganoderic acid were positively 
influenced by the temperature in 100% ethanol system while higher yields were obtained 
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in a medium extraction temperature in a water system. Ethanol concentrations had a 
positive effect on yields of both total extract and ganoderic acid H in a high extraction 
temperature environment (75 oC) while in a low extraction temperature (25 oC), ethanol 
concentrations negatively affected the yield of total extract and a medium ethanol 
concentration generated higher yield of ganoderic acid H. The optimal extraction 
parameters were predicted to be 100.00% ethanol at 60.22 °C for 6.00 h and 98.59% 
ethanol at 65.15 °C for 5.99 h for extraction of ganoderic acid H and total extract 
respectively. The variations of effects of extraction parameters on the amount of total 
extract and ganoderic acid H are likely a result of structural difference between the total 
extract and ganoderic acid H. It is possible that the response model of ganoderic acid H 
represents the corresponding model of triterpenoids as they share relatively similar 
structures as ganoderic acid H while the response model of total extract represents a 
combination model of polysaccharides, phenolic acids and triterpenoids, which may 
exhibit different properties in polarity and heat stability. In order to obtain efficient 
extraction of triterpenoids, the optimal extraction parameters for ganoderic acid H 
extraction was used for extraction of triterpenoids from Ganoderma lucidum.  
The extraction solvent discussed in this chapter was limited to ethanol so that data 
present in this chapter is comparable to reported yields of triterpenoids from single factor 
and orthogonal optimizations, which also used ethanol as extraction solvent [71]. In 
addition, ethanol is considered relatively non-toxic solvent for herbal extraction compared 
to other organic solvents such as hexane and chrolofrom. It was noticed that repeated 
extractions were able to increase the extraction efficiency as shown in Appendix 3. 
However, in order to reduce the workload during modeling extraction conditions, 
repeated extractions were not included in the experimental design using response surface 
methodology. Instead, extractions of triterpenoids under optimal extraction condition 
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obtained from response surface methodology were repeated three times to mixinize the 
extraction efficiency when large-scale extractions were conducted to obtain individual 





Figure 11. (a) Response surface plot of total extract (  ) as a function of extraction time (  ) 
and ethanol concentration (  ) at an extraction temperature of 50 °C (b) Response surface 
plot of total extract (  ) as a function of extraction time (  ) and extraction temperature (  ) 
in a solvent of 50% ethanol (c) Response surface plot of total extract (  ) as a function of 
ethanol concentration (  ) and extraction temperature (  ) in a 4 h extraction (d) Response 
surface plot of ganoderic acid H (  ) as a function of extraction time (  ) and ethanol 
concentration (  ) at an extraction temperature of 50 °C (e) Response surface plot of 
ganoderic acid H (  ) as a function of extraction time (  ) and extraction temperature (  ) in 
a solvent of 50% ethanol (f) Response surface plot of ganoderic acid H (  ) as a function of 
ethanol concentration (  ) and extraction temperature (  ) in a 4 h extraction. 
    
5.3.2 Isolation and Identification of Triterpenoids form Ganoderma lucidum 
The HPLC profile of fraction 2 obtained by flash chromatography was shown in 
Figure 10 (b), which was then used to isolate individual triterpenoids. A total of 23 
fractions were collected according to the HPLC profile and 7 triterpenoids were identified 
by ESI-MS and NMR analysis by comparing with the reported literature (NMR spectrums 
are included in Apendix 5) [32;65;77;128-130]. The molecular weight and structural 
details are: 
Ganoderic acid I  ESI-MS m/z: 531 [M-H]-, 1063[2M-H]-,513,469,451, 303, 265. 
1H NMR δ     : 3.21 (1H, dd, J=6.0, 11.2Hz, 3-H), 0.87 (3H, s, 5-H), 4.79 (1H, t, 
J=8.4Hz, 7-H), 1.14 (3H, s, 18-H), 1.22 (3H, s, 19-H), 1.39 (3H, s, 21-H), 0.85 (3H, s, 
31-H), 1.34 (3H, s, 32-H). 13 C NMR δ     : 34.9, 27.7, 78.3, 38.8, 49.2, 26.6, 66.9, 
156.7, 142.5, 38.7, 198.0, 50.6, 45.6, 59.7, 217.7, 36.1, 49.1, 19.0, 18.4, 73.0, 26.6, 52.6, 
210.4, 47.5, 34.2, 175.2, 16.9, 28.2, 15.4, 24.8. 
Ganoderic acid G  ESI-MS m/z: 531 [M-H]-, 1063[2M-H]-,513,469, 319, 303, 265. 
1H NMR δ     : 3.21 (1H, dd, J=7.6, 8.8Hz, 3-H), 4.77 (1H, t, J=8.4Hz, 7-H), 4.36 (1H, s, 
12-H), 0.79 (3H, s, 18-H), 1.30 (3H, s, 19-H), 1.13 (3H, d, J=6.4Hz, 21-H), 1.21 (3H, d, 
J=8.0Hz, 27-H), 1.03 (3H, s, 30-H), 0.87 (3H, s, 31-H), 1.44 (3H, s, 32-H). 13 C NMR 
δ     : 34.3, 27.5, 78.3, 38.6, 49.1, 26.7, 66.2, 157.3, 141.9, 38.3, 199.3, 77.8, 51.9, 60.3, 
64 
 
216.8, 38.2, 45.7, 11.9, 18.8, 28.7, 21.3, 48.3, 8.2, 46.2, 34.5, 176.1, 16.9, 28.1, 15.3, 
23.0. 
Ganoderic acid B  ESI-MS m/z: 515 [M-H]-, 1031[2M-H]-, 497, 453 , 303, 287, 
249. 1H NMR δ     : 3.21 (1H, dd, J=6.0, 11.2Hz, 3-H), 0.85 (3H, s,5-H), 4.79(1H, t, 
J=8.4Hz, 7-H), 1.00 (3H, s, 18-H), 1.21 (3H, s, 19-H), 0.98 (3H, d, J=6.0Hz, 21-H), 1.24 
(3H, d, J=6.4Hz, 26-H), 1.03 (3H, s, 31-H), 1.34 (3H, s, 32-H). 13 C NMR δ     : 34.3, 
28.1, 78.3, 38.8, 45.3, 27.6, 66.8, 156.8, 142.7, 45.5, 197.8, 50.3, 38.6, 59.4, 207.6, 40.9, 
49, 16.9, 17.4, 31.9, 19.6, 49.1, 217.5, 46.5, 34.8, 26.6, 179.5, 15.4, 24.4, 18.4. 
Ganoderic acid A  ESI-MS m/z: 515 [M-H]-, 1031[2M-H]-, 497, 435, 405, 301, 285. 
1H NMR δ     : 4.62(1H, t, J=8.0Hz, 7-H), 4.79 (1H, t, J=8.0Hz,15-H), 0.98 (3H, s, 
18-H), 1.25 (3H, s, 19-H), 0.88 (3H, d, J=6.0Hz, 21-H), 1.24 (3H, d, J=7.3Hz, 26-H), 1.1 
(3H, s, 30-H), 1.12 (3H, s, 31-H), 1.28 (3H, s, 32-H). 13 C NMR δ     : 35.6, 34.3, 208.5, 
46.8, 48.9, 29.2, 68.9, 159.0, 140.6, 46.6, 200.2, 51.7, 38.0, 54.0, 72.5, 36.3, 47.9, 17.3, 
19.5, 32.6, 19.3, 49.5, 216.9, 46.4, 34.5, 27.3, 179.8, 16.9, 20.7, 19.7. 
Ganoderic acid H  ESI-MS m/z: 571 [M-H]-, 1143[2M-H]-, 553, 511,467, 437, 319, 
303, 301. 1H NMR δ     : 3.25 (1H, dd, J=7.6, 8.8Hz, 3-H), 5.63 (1H, s, 12-H), 0.82 (3H, 
s, 18-H), 1.33 (3H, s, 19-H), 0.99 (3H, d, J=6.4Hz, 21-H), 1.21 (3H, d, J=8.0Hz, 27-H), 
1.03 (3H, s, 30-H), 0.88 (3H, s, 31-H), 1.73 (3H, s, 32-H). 13 C NMR δ     : 33.2, 27.3, 
77.2, 40.4, 51.4, 36.6, 198.8, 151.7, 145.7, 39.1, 193.9, 79.2, 47.9, 58.4, 205.7, 37.9, 44.7, 
12.2, 17.9, 29.4, 21.6, 48.3, 207.4, 46.4, 34.3, 176, 16.9, 27.9, 15.5, 21.3 
Ganoderenic acid D  ESI-MS m/z: 511 [M-H]-, 1023[2M-H]-, 493, 449, 301, 285, 
247, 149. 1H NMR δ     : 4.87 (1H, dd, J=7.6, 9.2Hz,7-H), 0.89 (3H, s, 18-H), 1.24 (3H, 
s, 19-H), 2.18 (3H, s, 21-H), 6.05 (1H, s, 22-H), 1.23 (3H, d, J=5.6Hz, 27-H), 1.13 (3H, s, 
30-H), 1.11 (3H, s, 31-H), 1.40 (3H, s, 32-H). 13 C NMR δ     : 35.6, 34.3, 216.5, 46.7, 
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48.8, 27.6, 66.3, 157.4, 141.4, 38.2, 197.8, 48.9, 45.9, 58.6, 216.4, 37.8, 49.7, 19.0, 18.1, 
153.8, 21.0, 124.6, 196.1, 47.5, 34.6, 180.6, 16.9, 27.0, 20.8, 24.7. 
Ganoderic acid D  ESI-MS m/z: 513 [M-H]-, 1027[2M-H]-, 495, 451, 301, 285, 247, 
149. 1H NMR δ     : 4.80 (1H, t, J=8.8Hz, 7-H), 0.99 (3H, s, 18-H), 1.20 (3H, s, 19-H), 
0.94 (3H, d, J=7.6Hz, 21-H), 1.21(3H, d, J=7.6Hz, 27-H), 1.06 (3H, s, 30-H), 1.03 (3H, s, 
31-H), 1.30 (3H, s, 32-H). 13 C NMR δ     : 35.6, 34.3, 217.6, 46.8, 48.9, 27.6, 66.3, 
157.8, 141.2, 38.2, 197.6, 50.1, 45.0, 59.3, 216.7, 41.0, 45.6, 17.6, 18.1, 32.0, 19.6, 48.9, 
207.6, 46.6, 34.3, 179.4, 16.9, 27.0, 20.8, 24.7. 
5.3.3 Cytotoxicity of Ganoderma lucidum Triterpenoids on Caco-2, Hep G2 and Hela 
cells 
The effects of 7 triterpenoids isolated from Ganoderma lucidum on Caco-2, Hep G2 
and HeLa cell growth are shown in Figure 12. The LC50 of each triterpenoids in each 
cells line was calculated as previously described in chapter 3 [131] and summarized in 
Table 10. As shown in Figure 12 and Table 10, ganoderic acid A, G and H did not 
effectively inhibit cell growth in the three cell lines up to a concentration of 0.70 mg/mL. 
Ganoderenic acid D was the most cytotoxic and had the lowest LC50s of 0.14±0.011, 
0.18±0.022 and 0.26±0.025 mg/mL in Hep G2 cells, Hela cells and Caco-2 cells 
respectively followed by ganoderic acid I and ganoderic acid D which had similar LC50s 
in the three cell lines tested. Ganoderic acid B showed selective cytotoxicity to Caco-2 
cells (0.36±0.070 mg/mL) and HepG2 cells (0.65±0.051 mg/mL) but not HeLa cells. The 
variation of LC50s of the 7 compounds in the three cell lines indicated that effects of 
these triterpenoids are cell specific. The respective chemical structures of the 7 
compounds are shown in Figure 10 (c). Compounds such as ganoderenic acid D that have 
an additional double bond between C-20 and C-22 in a triterpenoid structure are likely 
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relate to the increase cytotoxicity. This finding is consistent with the reported 
structure-activity relationship that the unsaturation of the side chain of Ganoderma 
lucidum alcohol derivatives is essential for the inhibitory effects of cell proliferation on 




Figure 12. Does-response relationship of ganoderic acid A, B, D, G, H and I and ganoderenic 
acid D in (a) HeLa cells, (b) Caco-2 cells and (c) Hep G2 cells after 72 h treatment measured 
by MTT assay. Values are expressed as mean ± SD. 
 
Table 10. Cytotoxicities of 7 triterpenoids isolated from Ganoderma lucidum on three human 
carcinoma cell lines obtained by MTT assay for 72 h treatment. Values are expressed as mean 
± SD. 
Compound 
LC50 of Cell lines (mg/mL) 
Hep G2 HeLa Caco-2 
ganoceric acid I 0.26±0.037 0.33±0.018 0.39±0.018 
ganoderic acid B 0.65±0.051 > 0.70 0.36±0.070 
ganoderic acid G > 0.70 > 0.70 > 0.70 
ganoderic acid A > 0.70 > 0.70 > 0.70 
ganoderic acid H > 0.70 > 0.70 > 0.70 
ganoderenic acid D 0.14±0.011 0.18±0.022 0.26±0.025 
ganoderic acid D 0.38±0.022 0.37±0.049 0.34±0.005 
 
The LC50 of ganoderenic acid D in Caco-2 cell was half the LC50 (0.528 ± 0.078 
mg/mL) we reported for a fractioned Ganoderma lucidum triterpenoid extract (fraction 2) 
in chapter 3 [133]. Ganoderic acid B, I and D were also more toxic than the reported 
Ganoderma lucidum triterpenoid extract in Caco-2 cells. Pure triterpenoids seem to 
possess more cytotoxicities than a triterpenoid mixture. 
A range of LC50s for these triterpenoids has been reported in the literature and are 
likely cell dependent. For example, in HeLa cells the LC50s of these 7 triterpenoids were 
reported to range from 8.72 to 20.3 μM which was one of twentieth the LC50s reported in 
this study. Alternatively an alcoholic extract from Ganoderma lucidum spores were 
shown to have an LC50 of 4.70 mg/mL, which is 10 times higher than the LC50s reported 
herein [39;119;134;135]. We used pure ganoderic acid H with a purity of 98% as a 
positive control in HeLa cells to benchmark the fractions cellular response. The 
dose-response curve and LC50 of the standard were consistent with the dose-response 




The RSM was applied to optimize extraction conditions of triterpenoids from 
Ganoderma lucidum for the first time with sufficient simulation modeling and predictions. 
The optimal extraction conditions for extracting total extract and ganoderic acid H were 
98.59% ethanol at 65.15 °C for 5.99 h and 100.00% ethanol at 60.22 °C for 6.00 h 
respective. We used the optimized extraction conditions of ganoderic acid H to obtain a 
ganoderic acid enriched crude extract and the crude extract under this condition was 
further separated by flash chromatography and semi-preparative HPLC to obtain 7 
individual triterpenoids. Three of the triterpenoids including ganoderic acid D and I and 
ganoderenic acid D were found to be cytotoxic does-dependently in Hep G2, HeLa and 
Caco-2 cells. An additional triterpenoid (ganoderic acid B) was also able to inhibit cell 
growth in Caco-2 cells and Hep-G2 but not in HeLa cells, indicating a cell-specific 
inhibitory effect. The most cytotoxic compound was ganoderenic acid D and influence 
cell growth in all cell lines and is likely a result of an addition double bond in its side 




CHAPTER 6 CYTOTOXIC TRITERPENOIDS AND ALCOHOL DERIVATIVES 
FROM GANODERMA LUCIDUM SHOW VARIOUS EFFECTS ON CELL 
CYCLE DISTRIBUTION AND APOPTOSIS IN THREE CULTURED HUMAN 
CARCINOMA CELLS  
Preface 
Selected portion of Chapter 6 are ready to be submitted as: 
Ruan, W.; Popovich, D. G. Cytotoxic triterpenoids and alcohol derivatives from 
Ganoderma lucidum show various effects on cell cycle distribution and apoptosis in three 
cultured human carcinoma cells. xxx. 2013. 
 
6.1 Introduction 
Triterpenoids and their alcohol derivatives from Ganoderma lucidum have garnered 
a lot of attention, as they are believed to contribute to the multiple pharmaceutical 
properties of this medicinal mushroom. These properties include anti-inﬂammatory, 
anti-tumor, anti-androgenic, anti- aldose-reductase and many other biological activities 
[7;132;136]. So far, hundreds of triterpenoids and their derivatives have been discovered 
and isolated from Ganoderma lucidum [65]. They are lanostane-type triterpenoids with 
attachment of various functional groups at different positions. Extracts of these 
triterpenoids and their derivatives have been reported to possess potent 
chemo-preventative potential affecting multiple regulatory mechanisms in cultured 
human carcinoma cell models [7]. These involved induction of autophagic and apoptotic 
cell deaths in human colon carcinoma cells, multidrug-resistant small-cell lung carcinoma 
cells, human gastric carcinoma cells and inhibition of metastasis in human hepatoma cells 
[47;48;137-139]. However, the specific bioactivity resulting from individual triterpenoids 
has not been effectively established. Research is slowed due to the complex and diverse 
chemical structures and wide variation in the active compounds. Furthermore, there are 
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many unidentified molecules presented in various extracts that can also contribute to the 
bioactivity. Elucidating the structure-activity relationship of these triterpenoids is vital for 
a comprehensive understanding of their bioactivities and mechanism of action. Slight 
modifications of chemical structure can influence bioactive response. For example, a 
carboxyl group on the side chain of Ganoderma lucidum triterpenoids has been suggested 
to be the essential functional group for exhibiting aldose reductase inhibitory activity; 
Ganoderic acid Df was found to inhibit aldose reductase to a greater extent compared to 
its methyl ester derivatives in vitro in which the carboxyl groups have been replaced 
[136]. Similarly, the number of hydroxyl groups at the side chain and C-3 carbonyl group 
of Ganoderma lucidum alcohol derivatives have been found to be crucial for their 
anti-androgenic effects and the unsaturation of the side chain to be necessary for 
suppression of cell growth in LNCaP human prostate carcinoma cells [132]. In chapter 3, 
we reported that Ganoderma lucidum triterpenoids reduced cultured Caco-2 cell growth 
and these effects were inversely correlated to the compound polarity and the C-23 
functional groups on the side chain in Caco-2 human colon carcinoma cells [140]. 
Therefore, in this chapter, the cytotoxic triterpenoids and the alcohol derivatives from 
Ganoderma lucidum were isolated using flash chromatography and semi-preparative 
HPLC and their associated bioactivities were investigated in three cultured human 
carcinoma cell models to evaluate possible structure-activity relationship. 
6.2 Materials and Methods 
6.2.1 Extraction and Isolation of Triterpenoids and Alcohol Derivatives 
The dry Ganoderma lucidum was purchased locally (slice of Ganoderma lucidum, 
chizhi, origin from China) and ground into a powder and the powder was refluxed with 
ethanol and separated by flash chromatography isolation as previously described in 
chapter 3 [141]. The triterpenoid-enriched fraction that had greatest cytotoxicity (fraction 
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3), was further separated by semi-preparative HPLC with a Waters system (Milford, MA, 
USA) coupled with Waters 515 HPLC pump, Waters 717 plus autosampler and Waters 
2996 PDA detector. A Waters XTerra Prep RP-18 column (7.8 mm × 100 mm, 5 μm 
particle size) (Milford, MA, USA) was applied with a flow rate of 2 ml/min. Gradient 
separation was employed with a combination of de-ionized water (A) and acetonitrile (B) 
as followed: 35% B - 45% B at 0 -5 min, 45 - 55% B at 5 - 15 min, 55% B - 70% B at 15 
-35 min, 70% B - 100% B at 35 -40 min and 100% B at 40 - 55 min. Samples were 
dissolved in 50% ethanol with a concentration of 10 mg/mL and an injection volume of 
200 μL was used. Individual triterpenoids and alcohol derivatives were collected 
according to the UV absorbance and each fraction was evaporate and lyophilized. For 
bioactivity tests, samples were dissolved in culture media containing 0.4% DMSO and 
passed through a 0.2 μm filter (Millex GP). 
6.2.2 Identification of Chemical Structures by ESI-MS and NMR  
To measure the molecular weights of triterpenoids and alcohol derivatives from 
Ganoderma lucidum, ESI-MS detection was conducted using a Bruker amaZonX IonTrap 
Mass Spectrometer (Bruker Daltonics Inc.). The ESI-MS conditions were set as follows: 
dry gas flow rate was at 8.0 mL/min; capillary voltage was at 4.5 kV; end plate offset was 
at -500 V, capillary temperature was set at 250 oC; flow rate was 0.2 mL/min and 
injection volume was 5 μL. Both positive and negative ionization was used and scanning 
mass spectra was ranged from 70 to 2000 m/z.  
To identify the chemical structures of triterpenoids and the alcohol derivatives, 2-3 
mg samples was dissolved in 600 μL deuterated chloroform and went through NMR 
analysis with a Bruker AMX500 MHz NMR Spectrometer (Bruker BioSpin GmbH). 1H 
and DEPT 13C NMR spectra were measured and chemical shifts were expressed in terms 
of δ (ppm).  
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6.2.3 Cell Culture 
The three human carcinoma cells (Hep G2 cells, Caco-2 cells and HeLa cells) were 
purchased from American Type Culture Collection (Manassas, VA, USA). Cells were 
cultured using DMEM (Caisson Laboratories, Inc.) with supplement of 10% fetal bovine 
serum (Hyclone UK Ltd.) and 100 units/mL of penicillin /streptomycin (Gibco, 
Invitrogen). The cells were maintained at a concentration between 2 × 105 and 1 × 106 
cells/mL and sub-cultured every 3 - 4 days after confluency with 0.25% (w/v) trypsin - 
0.53 mM ethylenediaminetetraacetic acid solution (Gibco, Invitrogen). Viable cells were 
assessed by staining cells with 0.04% trypan blue exclusion dye (MP Biomedicals) and 
counted in a hemocytometer. 
6.2.4 MTT Assay and Cell Cycle Analysis 
Effects of Ganoderma lucidum triterpenoids and the alcohol derivatives on cell 
growth were analyzed using MTT assay as previously described in chapter 5. Briefly, a 
seeding concentration of 2.0 × 104, 2.5 × 104 and 1.5 × 104 cells/mL for Caco-2, Hep G2 
and HeLa cells respectively were used in 96-well plates. Cells were treated with each 
compound at various concentrations for 72 h after 24 h adherence. Untreated cells acted 
as controls. The media was removed and replaced by MTT (Sigma) after treatments and 
the resulting formazan crystals were dissolved with SDS (10%) in HCl (0.01 N). The 
optical density was measured at absorbance of 570 nm and 650 nm by a micro-plate 
reader (Multiskan Spectrum). 
For cell cycle analysis, cells were seeded in 6-well plates at concentrations of 2.0 × 
104, 2.5 × 104 and 1.5 × 104 cells/mL for Caco-2, Hep G2 and HeLa cells respectively and 
treated with each compound for 72 h after 24 h adherence. Untreated cells acted as 
controls. After treatments, cells were harvested, fixed and stained as previous described in 
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chapter 3 [142]. Samples were analyzed by Guava PCA flow cytometry with CytoSoft 
software (Guava Technologies, Inc.). 
6.2.5 TUNEL Assay 
    To quantify the DNA fragmentation induced by apoptotic cell death, TUNEL assay 
was conducted using a commercial detection kit as previous described in chapter 3 [143]. 
6.2.6 Statistical Analysis 
Results of MTT assay, cell cycle analysis and TUNEL assay were expressed as 
means ± SD. ESI-MS detection, MTT assay, cell cycle analysis and TUNEL assay were 
conducted in three separate experiments with three replicate. One-way ANOVA with 
Duncan post hoc comparison of means and independent-samples T test were used for 
statistical analysis. Significance was determined at p < 0.05 using the SPSS statistical 
software (v12.0, Chicago, IL, USA). 
6.3 Results 
6.3.1 Isolation and Identification of Triterpenoids and the Alcohol Derivatives  
The representative HPLC chromatograph for isolation of triterpenoids and the 
alcohol derivatives is shown in Figure 13. Each peak was collected as one fraction and a 
total of 6 fractions were identified as single compounds by ESI-MS and NMR analysis. 
Chemical structures of these compounds were identified by comparing their molecular 
weights and chemical shifts to the report literature values [5;74;76;144;145]. The 
chemical structures of identified compounds are shown in Figure 14 and the ESI-MS and 
NMR data are as follow (NMR spectrums are included in Apendix 5): 
ganolucidic acid E  ESI-MS m/z: 485.6 [M+H]+, 483.3 [M-H]-, 967.6[2M-H]-. 1H 
NMR δ     : 2.74 (1H, d, J=17.5Hz, 12-H), 4.39 (1H, dd, J=5.7, 9.5Hz, 15-H), 0.89 (3H, 
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s, 18-H), 1.12 (3H, s, 19-H),0.87 (3H, d, J=5.7Hz, 21-H), 1.12 (3H, s, 28-H), 1.08 (3H, s, 
29-H), 1.18 (3H, s, 30-H). DEPT 13 C NMR δ     : 35.1 (1-C), 34.2 (2-C), 51.5 (5-C), 
18.7 (6-C), 29.6 (7-C), 51.8 (12-C), 73.0 (15-C), 38.8 (16-C), 48.9 (17-C), 17.2 (18-C), 
18.8 (19-C), 35.9 (20-C), 18.0 (21-C), 34.5 (22-C), 25.7 (23-C), 144.7 (24-C), 12.2 
(27-C), 27.8 (28-C), 20.6 (29-C) , 19.0 (30-C). 
lucidumol A  ESI-MS m/z: 473.7 [M+H]+, 471.3 [M-H]-. DEPT 13 C NMR δ     : 
35.4 (1-C), 34.4 (2-C), 50.4 (5-C), 37.2 (6-C), 23.9 (11-C), 30.1 (12-C), 28.7 (15-C), 31.9 
(16-C), 49.0 (17-C), 15.9 (18-C), 24.9 (19-C), 36.6 (20-C), 18.9 (21-C), 33.5 (22-C), 28.6 
(23-C), 79.6 (24-C), 23.2 (26-C), 26.6 (27-C), 25.3 (28-C), 21.4 (29-C) , 17.9 (30-C). 
ganodermanontriol  ESI-MS m/z: 531.8 [M-H]-. DEPT 13 C NMR δ     : 36.6 
(1-C), 34.9 (2-C), 50.7 (5-C), 23.7 (6-C), 120.0 (7-C), 117.2 (11-C), 37.8 (12-C), 27.9 
(15-C), 31.5 (16-C), 51.0 (17-C), 15.7 (18-C), 22.5 (19-C), 36.5 (20-C), 18.6 (21-C), 33.5 
(22-C), 28.9 (23-C), 79.3 (24-C), 67.7 (26-C), 22.5 (27-C), 25.5 (28-C), 22.1 (29-C) , 
25.4 (30-C). 
7-oxo-ganoderic acid Z  ESI-MS m/z: 471.7 [M+H]+, 470.0 [M-H]-, 939.7 [2M-H]-. 
DEPT 13 C NMR δ     : 34.8 (1-C), 27.4 (2-C), 49.8 (5-C), 36.6 (6-C), 23.7 (11-C), 30.1 
(12-C), 32.0 (15-C), 28.8 (16-C), 48.9 (17-C), 15.8 (18-C), 18.4 (19-C), 36.2 (20-C), 18.6 
(21-C), 34.8 (22-C), 25.9 (23-C), 145.5 (24-C), 12.1 (27-C), 25.0 (28-C), 27.4 (29-C) , 
15.3 (30-C). 
15-hydroxy-ganoderic acid S  ESI-MS m/z: 467.8 [M-H]-, 935.6 [2M-H]-. DEPT 13 
C NMR δ     : 36.6 (1-C), 34.8 (2-C), 50.5 (5-C), 23.6 (6-C), 121.2 (7-C), 116.9 (11-C), 
38.5 (12-C), 74.6 (15-C), 40.0 (16-C), 48.9 (17-C), 16.0 (18-C), 22.2 (19-C), 35.9 (20-C), 
18.3 (21-C), 34.7 (22-C), 25.8 (23-C), 145.1 (24-C), 12.1 (27-C), 17.0 (28-C), 25.4 
(29-C) , 22.5 (30-C). 
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ganoderic acid DM  ESI-MS m/z: 469.7 [M+H]+, 937.4[2M+H]+,467.3 [M-H]-, 
935.7[2M-H]-. DEPT 13 C NMR δ     : 35.4 (1-C), 34.4 (2-C), 50.4 (5-C), 37.2 (6-C), 
23.8 (11-C), 30.1 (12-C), 28.7 (15-C), 31.9 (16-C), 49.0 (17-C), 15.9 (18-C), 17.9 (19-C), 
36.2 (20-C), 18.6 (21-C), 34.7 (22-C), 25.9 (23-C), 145.4 (24-C), 12.1 (27-C), 25.4 
(28-C), 22.4 (29-C) , 24.9 (30-C). 
 
Figure 13. Representative HPLC chromatograph of fraction 3 from Ganoderma lucidum by 
semi-preparative HPLC. Peak numbers refer to the identified individual triterpenoids and the 
alcohol derivatives. 1, ganolucidic acid E; 2, lucidumol A; 3, ganodermanontriol; 4, 
7-oxo-ganoderic acid Z; 5, 15-hydroxy-ganoderic acid S; 6, ganoderenic acid DM. 
 
 
Figure 14. Chemical structures of identified compounds from Ganoderma lucidum. 
 
6.3.2 The Effects of Ganoderma lucidum Triterpenoids and the Alcohol Derivatives on 
Three Human Carcinoma Cell Growth 
The effect of isolated triterpenoids and the alcohol derivatives from Ganoderma 
lucidum on Caco-2, Hep G2 and HeLa cell growth are shown in the dose-response curves 
in Figure 15. The LC50 values are determined by plotting cell viabilities against log 
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concentrations (graph not shown) and shown in Table 11. All six compounds are able to 
inhibit cell growth in a dose dependent manner in all three cell lines. Hep G2 cells are the 
most sensitive cell line with less cell variability at the same concentration treatment 
compared to the other two cell lines. Ganodermanontriol had the greatest cell growth 
inhibitory effect on Hep G2 cell with an LC50 of 20.87 ± 1.48 µM, while 
15-hydroxyl-ganoderic acid S exhibits the most cell growth inhibitory effect in HeLa and 






Figure 15. Dose-response relationship of 6 triterpenoids and the alcohol derivatives from 
Ganoderma lucidum in (a) HeLa cells, (b) Caco-2 cells and (c) Hep G2 cells measured by 
MTT assay for 72 h treatment. Values are expressed as mean ± SD. 
 
Table 11. Cytotoxicities of 6 triterpenoids and the alcohol derivatives from Ganoderma 
lucidum on three human carcinoma cell lines from MTT assay for 72 h treatment. Values are 
expressed as mean ± SD. 
Compound 
LC50s of Cell lines (µM) 
Heg G2 HeLa Caco-2 
ganolucidic acid E 28.28±2.57 32.25±5.55 53.07±4.07 
lucidumol A 38.58±5.27 42.07±4.27 84.36±9.97 
ganodermanontriol 20.87±1.48 36.50±4.67 36.77±2.79 
7-oxo-ganoderic acid Z 22.08±2.23 45.88±3.29 30.83±2.54 
15-hydroxy-ganoderic acid S 21.52±1.81 21.17±1.81 30.38±1.44 
ganoderic acid DM 35.34±4.46 55.61±0.88 63.72±8.17 
 
6.3.3 Cell Cycle Distribution Regulated by Ganoderma lucidum Triterpenoids and the 
Alcohol Derivatives  
The corresponding cell cycle distributions of three human carcinoma cells treated 
with the six compounds are shown in Figure 16. All six compounds are able to 
significantly (p < 0.05) accumulate cell populations at sub-G1 phase in HeLa cells with 
an increase percentage range from 5.11% for ganoderic acid DM to a high 22.06% for 
15-hydroxy-ganoderic acid S. Four compounds which are ganodermanontriol, 
7-oxo-ganoderic acid Z, 15-hydroxy-ganoderic acid S and ganoderic acid DM show 
significantly (p < 0.05) increased sub-G1 cell percentages with a range of 7.90% 
(ganodermanontriol) to 9.53% (7-oxo-ganoderic acid Z) in Caco-2 cells, while none of 
the compound caused any significant changes in sub-G1 cell accumulation in Hep G2 
cells. All six compounds cause a significant (p < 0.05) reduction of cells at G0/G1 phase 
in both Caco-2 and HeLa cells with decreased percentages ranged from 3.9% (lucidumol 
A) to 20.6 % (15-hydroxy-ganoderic acid S) but not for treatments with lucidumol A, 
ganodermanontriol and 15-hydroxy-ganoderic acid S in Hep G2 cells. Conversely, 
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lucidumol A causes a G0/G1 arrest in Hep G2 cells with an increase in cell percentage of 
2.33% compared to the control cells while ganodermanontriol and 15-hydroxy-ganoderic 
acid S do not cause significant changes at G0/G1 phase in Hep G2 cells. Compared to the 
control cells, cell percentages in the S phase do not change significantly in HeLa cell, 
while treatments of ganolucidic acid E, ganodermanontriol, 15-hydroxy-ganoderic acid S 
and ganoderic acid DM have a significant (p < 0.05) increase in cells at S phase in Caco-2 
cells. Lucidumol A, 7-oxo-ganoderic acid Z and ganoderic acid DM increase cell 
percentages at S phase in Hep G2 cells. Treatments of ganolucidic acid E, lucidumol A, 
ganodermanontriol and ganoderic acid DM cause a G2/M arrest in Caco-2 cells 
(increment ranged from 2.43% for ganodermanontriol to 14.95% for lucidumol A) and 
ganodermanontriol and ganoderic acid DM result in G2/M arrest in HeLa cells with 
increment of 7.10% and 14.20% respectively. Similarly, ganolucidic acid E and 
15-hydroxy-ganoderic acid S induce an accumulation of G2/M cells in Hep G2 cells but 
to a smaller extent compared to similar treatment in the other two cell lines, with 
increment of 2.78% and 2.28% respectively. Additionally, a significant (p < 0.05) 
reduction in cells at G2/M phases are observed with treatments of ganolucidic acid E and 
lucidumol A in HeLa cells and treatment of lucidumol A in Hep G2 cells with reduced 
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Figure 16. Cell cycle distributions of Caco-2, Hep G2 and HeLa cells for 72 h treatments of 6 
triterpenoids and the alcohol derivatives from Ganoderma lucidum at their respective LC50 
concentrations obtained by MTT assay. Values are expressed as mean ± SD. An asterisk 
represents significant differences (p < 0.05) in the same phases within the same cell line 
compared to control values. 
 
6.3.4 Induction of Apoptosis by Ganoderma lucidum Triterpenoids and the Alcohol 
Derivatives on Caco-2 and HeLa Cells 
Since sub-G1 accumulations were observed with treatments of triterpenoids and the 
alcohol derivatives in Caco-2 and HeLa cells, which indicated possible involvement of 
DNA fragmentation in the process of cell death, the TUNEL assay was conducted to 
quantify the resulting apoptotic DNA fragments. Results of the flow cytometry analysis 
are shown in Figure 17 and the cell percentages of apoptotic and non-apoptotic 
populations are summarized in Table 12. All tested compounds induce a significant (p < 
0.05) increase apoptotic cell percentage from 3.47% to 43.03% and a corresponding 
reduction of non-apoptotic cell percentages compared to untreated control cells in both 
cell lines. 15-hydroxy-ganoderic acid S is the most potent apoptotic inducer while 
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Figure 17. Representative flow cytometry analysis of TUNEL assay for 72 h treatments of 
identified triterpenoids and the alcohol derivatives from Ganoderma lucidum at their 
respective LC50 concentrations. A, control treatment of Caco-2 cells; B-E, treatment of 
ganodermaonontriol, 7-oxo-ganoderic acid Z, 15-hydroxy-ganoderic acid S and ganoderic 
acid DM on Caco-2 cells respectively; F, control treatment of HeLa cells; G-L, treatment of 
ganolucidic acid E, lucidumol A, ganodermaonontriol, 7-oxo-ganoderic acid Z, 









Table 12. Cell percentages of TUNEL assay in Caco-2 and HeLa cells for 72 h treatments of 
triterpenoids and the alcohol derivatives from Ganoderma lucidum at their respective LC50 
concentrations. Values are expressed as mean ± SD. An asterisk represents significant 
differences (p < 0.05) in the same group within the same cell line compared to control values. 
Compound 
TUNEL Assay in Caco-2 cells 
cell percentage (%) 
TUNEL Assay in HeLa cells 
cell percentage (%) 
Non-apoptotic Apoptotic  Non-apoptotic Apoptotic  
control 94.05±0.71 5.86±0.71 97.09±1.92 2.86±1.88 
ganolucidic acid E - - 83.20±0.73* 16.80±0.73* 
lucidumol A - - 87.78±1.17* 12.06±1.22* 
ganodermanontriol 74.34±1.62* 25.45±1.34* 93.50±2.08* 6.33±2.02* 
7-oxo-ganoderic acid Z 73.65±1.41* 26.13±1.24* 73.29±0.39* 26.51±0.43* 
15-hydroxy-ganoderic acid S 66.60±1.00* 33.09±0.58* 53.70±0.44* 45.90±0.45* 
ganoderic acid DM 64.20±3.47* 35.70±3.45* 62.40±0.60* 37.10±0.83* 
 
6.4 Discussions 
Six triterpenoids and alcohol derivatives have been isolated from the ethanol extract 
of Ganoderma lucidum. This thesis is the first to report their bioactive effects in three 
distinct cancer cell models. LC50s of the six compounds in Caco-2, Hep G2 and HeLa 
cells ranged from 20.87 µM to 84.36 µM. The range of the LC50s is consistent to 
reported cytotoxicity of Ganoderma lucidum triterpenoids in other cell models. For 
instant, the LC50 of ganoderic acid Me was reported to be 36.9 µM in HCT-116 cells 
[49]. The LC50s of ganoderic acid Mf and S ranged from 19.5 µM to 39.1 µM in HeLa 
cells while the LC50 of an alcohol derivative, ganoderiol F was found to be 17 µM in 
Hep G2 cells [50;52]. The LC50s of all the six individual triterpenoids and alcohol 
derivatives are much lower compared to the LC50 (0.348 ± 0.032 mg/mL) of their parent 
crude extract as repoterd in chapter 3 [146]. Among the three cell models, Hep G2 cells 
was most sensitive to the cytotoxic effects of the six compounds while Caco-2 cells was 
the most resistant one which was evident by relatively high LC50s for all six compounds. 
The relatively cytotoxic resistance of HeLa and Caco-2 cells may possibly due to their 
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aneupliod nature and chromosome instability, compared to a relatively near-diploid 
karyotpe of Hep G2 cells [147]. Aneuploid and chromosome instability were believed to 
contribute to the acquisition of drug resistance by enhancing adaptation capacity to 
withstand cellular stresses [148;149]. LC50s of the six compounds in Hep G2 cells were 
found to be in the following order: ganodermanontriol < 15-hydroxy-ganoderic acid S < 
7-oxo-ganoderic acid Z < ganolucidic acid E < ganoderic acid DM < lucidumol A. While 
in HeLa cells, it was 15-hydroxy-ganoderic acid S < ganolucidic acid E < 
ganodermanontriol < lucidumol A <7-oxo-ganoderic acid Z < ganoderic acid DM. In 
addition, in Caco-2 cells, the order was 15-hydroxy-ganoderic acid S < 7-oxo-ganoderic 
acid Z < ganodermanontriol < ganolucidic acid E < ganoderic acid DM < lucidumol A. 
The order of relative potency in the six compounds seemed to be similar in Hep G2 and 
Caco-2 cells while a completely different order was observed in HeLa cells, suggesting 
that effects of six triterpenoids and alcohol derivatives are likely cell specific. Though no 
obvious structured-activity relationship was observed, it was noticed that ganoderic acid 
DM and lucidumol A which were less cytotoxic in all three cell lines both have oxy 
groups at position C-3 and C-7 of the ring structure. The oxy groups in these two 
positions are likely to interfere with the biding capacity of triterpenoids to cellular 
constituents possibly protein domains that could trigger the toxic effects and thus 
contribute to reduced cytotoxicity. Similar evidence of structure-activity relationship has 
been reported for 3-oxo ursolic acid derivative of ursolic acid exhibited less cytotoxicity 
in HeLa cells than ursolic acid. Ursolic acid has a hydroxyl group at C-3 and a hydrogen 
donor group at either C-3 and/or C-28 and this has been reported to be essential for the 
cytotoxic properties [150]. Multiﬂorane-type triterpenoids derived from Trichosanthes 
kirilowii with an oxy group at C-3 had impaired activity compared to a hydroxyl group. 
Furthermore, the presence of oxy group at either C-3 and/or C-11 reduced the inhibitory 
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effects of these triterpenoids on Epstein–Barr virus early antigen activation induced by 
the tumor promoter 12-O-tetradecanoylphorbol-13-acetate in Raji cells [151]. 
Similar to the cytotoxic effects of the triterpenoids and alcohol derivatives, their 
effects on cell cycle distributions were variable and different with respects to structure 
and cell line. For example, lucidumol A caused an accumulation of sub-G1 cell 
populations in HeLa cells but not in Caco-2 and Hep G2 cells. Lucidumol A also caused a 
G0/G1 arrest in Hep G2 cells while another alcohol derivative ganodermanontriol did not 
affect the cell cycle distribution in the same cell line. Similarly, ganoderic acid Mf was 
reported to cause a G0/G1 arrest while ganoderic acid S triggered a cell cycle arrest at S 
phase in HeLa cells [50]. Conversely, none of the six sample treatments in our study 
caused either G0/G1 or S phase arrest in HeLa cells but instead caused significant 
reductions in the percentage of cells at the G0/G1 phase. Similar to our reported G0/G1 
arrest from lucidumol A in Hep G2 cells, another alcohol derivative, ganoderiol F, was 
reported to cause a cell cycle arrest at the G0/G1 phase [52]. No conclusive 
structure-activity relationship could be observed in this study. However, the number of 
hydroxyl groups on the side chain for ganoderma alcohols seem to influence the cell cycle 
distribution in Hep G2 cells, in which ganoderma alcohols with two hydroxyl groups on 
the side chain caused G0/G1 arrest while those with three hydroxyl groups do not. It was 
noticed that treatments using all six compounds failed to cause any significant 
accumulated sub-G1 cells in Hep G2 cells even though Hep G2 was the most sensitive 
cell line. This finding indicated that the cytotoxic effect of Ganoderma lucidum 
triterpenoids and the alcohol derivatives were not necessarily correlated to apoptotic cell 
death. 
In HeLa and Caco-2 cells, results from the TUNEL assay confirmed apoptotic cell 
death. The percentages of apoptotic cells in all treatments in Caco-2 cells were similar 
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while percentages of apoptotic cells in treatments in HeLa cells varied. Among the six 
compounds, ganodermanontriol treated cells increased apoptotic cells by 3.47% 
compared to control in HeLa cells, indicating the accumulated sub-G1 cells may only be 
partially attributed to apoptotic cell death. 
Six triterpenoids and the alcohol derivatives have been successfully isolated from a 
Ganoderma lucidum extract and their effects on cell growth and apoptosis were measured 
in three distinct cultured carcinoma cell lines. Theses triterpenoids and alcohol derivatives 
exhibited diverse regulatory effects in the cell growth and cell cycle distribution in 
Caco-2, Hep G2 and HeLa cells. Some were able to induce apoptotic cell death in Caco-2 
and HeLa cells but not Hep G2 cells. The cell specific effects of these compounds did not 
show any obvious structure-activity relationship. It is likely, that there is multiple 
activation of different cellular regulation and the variation is depending on cell type. 
Further study is needed to elucidate their underlying regulation mechanisms in different 
cell models. This chapter provides scientific evidence on the bioactivity of six 
Ganoderma lucidum triterpenoids and alcohol derivatives in cultured human carcinoma 






CHAPTER 7 GANODERMA LUCIDUM TRITERPENOIDS AND THE 
ALCOHOL DERIVATIVES STIMULATE CASPASE ACTIVATION AND 
CYTOCHROME C RELEASE, INDUCE APOPTOSIS AND ALTER MULTIPLE 
CELLULAR PATHWAYS IN CULTURED HUMAN CARCINOMA CELLS 
Preface 
Selected portion of Chapter 7 are ready to be submitted as: 
Ruan, W.; Wei, Y.; Popovich, D. G. Ganoderma lucidum triterpenoids and the alcohol 
derivatives stimulate caspase activation and cytochrome c release, induce apoptosis and 
alter multiple cellular pathways in cultured human carcinoma cells. xxx. 2013. 
 
7.1 Introduction 
Apoptosis, also known as programmed cell death, is a mode of cell death without 
associated inflammation for cell clearance to maintain particular cell number and tissue 
size in normal tissue development and homoeostasis [152]. The apoptotic cell death is 
typically characterized by cell shrinkage, nuclear chromatin condensation, DNA 
fragmentation and formation of apoptotic bodies [153]. To date, two key pathways are 
believed to be responsible for apoptotic cell death [154-158]. One pathway is the extrinsic 
pathway, which involves activation of receptors in the death receptors subfamily and 
subsequent recruitments of initiator caspases. The other pathway, which involves p53 
activation, is intrinsic and mediated through mitochondria. Both pathways are able to 
result in alteration of protein expressions in Bcl-2 family that subsequently cause 
permeabilization of mitochondrial outer membrane to release multiple apoptogenic 
proteins including cytochrome c and apoptosis inducing factor and eventually stimulate 
downstream effector caspases to regulate the process of cell death. Due to the complex 
and multiple steps involved in the apoptotic pathways, minor alteration in these 
transduction signaling could impair normal apoptosis regulation and result in 
89 
 
carcinogenesis [159]. Thus, the induction of apoptotic has become the primary strategy 
for antitumor agents to exert antitumor effect against carcinoma cells in cancer 
chemotherapy [160-162].  
Bioactive components from medicinal plants, particularly phytochemicals, have 
gained increasing research interests for their effective anticancer properties [163;164]. 
Growing experimental evidence has indicated that some of the phytochemicals can inhibit 
cell growth and induce apoptosis in cancer cells in vitro [165-168]. Triterpenoids from 
Ganoderma lucidum which is a medicinal mushroom used as folk remedy in ancient Asia, 
has been reported to possess anti-tumor effects in multiple carcinoma cell lines via 
diverse regulation mechanisms [7]. A triterpene-enriched extracts from Ganoderma 
lucidum was reported to induce apoptotic cell death in SW620 cells by up regulation of 
p53, increment of BAX/Bcl-2 ratio and activation of caspase-3 activity [48]. Similar 
effects were observed in treatments of ganoderic acid Me in HCT-116 cells, ganoderic 
acid T in 95-D cells and ganoderic acid Mf and S in HeLa cells, all of which stimulated 
apoptotic cell deaths through a mitochondria-mediated pathway [49;50;169]. However, 
the possibility of involvement of other regulation pathways and existence of cell-specific 
effects of these Ganoderma lucidum triterpenoids are not well understood. In chapter 6, 
we have indicated that induction of apoptosis by Ganoderma lucidum triterpenoids and 
the alcohol derivatives was cell specific and likely to involve multiple regulation of 
cellular signaling. To further elucidate the apoptosis regulation mechanisms by 
Ganoderma lucidum triterpenoids and the alcohol derivatives, this chapter examined the 
possible involvement of caspase activation, membrane protein externalization and release 




7.2 Materials and Methods 
7.2.1 Isolation and Chemical Characterization of Ganoderma lucidum Triterpenoids 
and the Alcohol Derivatives 
Six triterpenoids and the alcohol derivatives including ganolucidic acid E, lucidumol 
A, ganodermanontriol, 7-oxo-ganoderic acid Z, 15-hydroxy-ganoderic acid S and 
ganoderic acid DM were obtained by flash chromatography and semi-preparative HPLC 
from an ethanol extract of Ganoderma lucidum as previously described in chapter 6. 
Their molecular weights and chemical structures were determined and confirmed by 
ESI-MS and 1H and DEPT 13C NMR analysis and compared to references as previously 
described in chapter 6. 
7.2.2 Cell Culture 
Three cultured human carcinoma cells (Hep G2 cells, Caco-2 cells and HeLa cells) 
were originated from American Type Culture Collection (Manassas, VA, USA). They 
were cultured as stated in chapter 6. Their viabilities were assessed with a staining of 
0.04% trypan blue exclusion dye (MP Biomedicals) and counted in a hemocytometer. 
7.2.3 Multi-caspase Apoptotic Assay 
Multi-caspase apoptotic assay were conducted using a multi-caspase detection kit 
(Guava Technologies, Inc.) and analyzed on a Guava PCA flow cytometry (Guava 
Technologies Inc.) as previously described in chapter 3 [170]. Briefly, cells were seeded 
in 6-well plates and treated with triterpenoids and alcohol derivatives that induce 
apoptosis at their respective previously reported LC50 concentrations ( chapter 6) for 48 h 
after 24 h adherence. Untreated cells acted as controls. After treatment, cells were 
harvested by trypsinization and centrifugation. The cell pellets were then washed with 
PBS, adjusted to a concentration of 5× 105 cells/mL and firstly stained with 
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SR-VAD-FMK reagent (Guava Technologies Inc.) with a subsequent second staining of 
7-AAD reagent (Guava Technologies Inc.). 
7.2.4 Annexin-V-Fluorescein Isothiocyanate (FITC)/PI Apoptotic Asssay 
To assess the translocation of phosphatidylserine during apoptosis, an Annexin 
V-FITC Apoptosis detection Kit (eBioscience, Inc., San Diego, CA, USA) was used 
according to the manufacture’s instruction with minor modification. Briefly, cells were 
seeded in 96-well plates and treated with the six triterpenoids and the alcohol derivatives 
at their respective previously reported LC50 concentrations for 72 h. Untreated cells acted 
as controls. Cells were washed with the binding buffer and co-stained with 5 µL annexin 
V-FITC reagent and 10 µg/mL PI at room temperature for 30 min. After staining, cells 
were visualized by a LSM 510 laser scanning confocal microscope (Carl Zeiss, 
Heidelberg, Germany) with a a Zeiss LD Plan-Neofluar 20 × objective (Carl Zeiss). The 
excitation wavelength was set at 488 nm and 543 nm and the emission wavelength was 
510 nm and 620 nm for annexin V-FITC and PI respectively. 
7.2.5 Detection of Cytochrome-c Release by Confocal Microscope 
    Cells were grown in 96-well plates and treated with the six triterpenoids and the 
alcohol derivatives as mentioned above. After treatment, cells were washed with PBS and 
stained with 300 nM MitoTracker Deep Red FM (Life Technologies, Molecular Probes, 
Inc., Eugene, OR, USA) in DMEM in a 5% CO2 incubator at 37°C for 35 min. After 
staining the mitochondria, cells were washed with PBS and fixed with 4% formaldehyde 
for 10 min at room temperature, followed by blocking of nonspecific bindings with 5% 
BSA (Sigma) for 30 min at 37°C in a 5% CO2 incubator. Cells were then stained with 5 
µg Anti-Cytochrome C FITC reagent (eBioscience, Inc.) for each sample for 60 min at 
37°C in the incubator. The double-labeled cells were then visualized by a LSM 510 laser 
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scanning confocal microscope (Carl Zeiss) with a Zeiss LD Plan-Neofluar 20× objective 
(Carl Zeiss). The excitation wavelength was set at 488 nm and 633 nm and the emission 
wavelength was 510 nm and 690 nm for Anti-Cytochrome C FITC and MitoTracker Deep 
Red FM respectively. 
7.2.6 Luciferase Reporter Arrays Analysis 
7.2.6.1 Transient Transfection 
Cells were seeded at concentrations of 5× 104 and 3× 105 cells/mL for HeLa and Hep 
G2 cells respectively in 96-well plates. A Cignal Finder Cancer 10-pathway reporter 
system (Qiagen, Valencia, CA, USA) which contains an inducible transcription 
factor-responsive firefly luciferase reporter and the constitutively expressing Renilla 
construct were employed 24 h after seeding. Transient transfections were conducted using 
the lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s instructions. 
7.2.6.2 MTT Assay 
To determine the doses applied in the luciferase reporter assay, MTT assay was 
conducted with cell seeding concentrations of 5× 104 and 3× 105 cells/mL for HeLa and 
Hep G2 cells respectively in 96-well plates. Cells were treated with the six triterpenoids 
and the alcohol derivatives at various concentrations from 20 µM to 400 µM for 18 h 
after 24 h adherence. Untreated cells acted as controls. After treatment, cells were treated 
with MTT solution and their viabilities were assessed as previously describe in chapter 3 
[171]. 
7.2.6.3 Luciferase Assay 
After transient transfections, cells were treated with six triterpenoids and the alcohol 
derivatives for 18 h in their respective LC50 concentrations obtained by MTT assay as 
93 
 
mentioned above while untreated cells acted as controls. The cells were then wash with 
PBS, lysed and the luciferase activities were measured using the Dual Luciferase Assay 
system (Promega, Madison, WI, USA) with a BioTek Synergy HT Multidetection 
Microplate Reader (BioTek Instruments, Inc., Winooski, VT, USA). The luminescent 
signals of the firefly luciferase were normalized to renilla luciferase by the firefly/renilla 
ratios and the fold change of relative luciferase units were determined by dividing the 
firefly/renilla ratios of samples to control cells. 
7.2.7 Statistical Analysis 
Results of Multi-caspase apoptotic assay, MTT assay and luciferase reporter array 
were expressed as means ± SD. ESI-MS detection, Multi-caspase apoptotic assay, MTT 
assay and luciferase reporter array were conducted in three separate experiments with 
three replicate. Confocal observations of annexin-V and cytochrome c were conducted in 
two separate experiments with duplicate. Statistical analysis was conducted using 
one-way ANOVA with Duncan post hoc comparison. Significance was determined at p < 
0.05 using the SPSS statistical software (v12.0, Chicago, IL, USA). 
7.3 Results 
7.3.1 Response of Triterpenoids and the Alcohol Derivatives in Multi-caspase 
Apoptotic Assay  
To quantify the stages of apoptosis and possible involvement of caspase cascade 
induced by Ganoderma lucidum triterpenoids and the alcohol derivatives in HeLa and 
Caco-2 cells, multi-caspase apoptotic assay was conducted and the results of the flow 
cytometry analysis are shown in Figure 18 and Table 13. Compared to the controls, 
treatments of all tested samples are able to significantly (p < 0.05) reduce the percentage 
of viable cells from 10.51% to 35.67% and from 29.26% to 40.78% in Caco-2 and HeLa 
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cells respectively. Treatments of all six compounds also significantly (p < 0.05) increase 
cell percentages in mid and late-apoptotic stages in HeLa cells with increase ranges of 
6.75% to 35.32% and 4.56% to 34.36% respectively. Similarly, treatments of 
ganodermanontriol, 7-oxo-ganoderic acid Z, 15-hydroxy-ganoderic acid S and ganoderic 
acid DM significantly (p < 0.05) stimulate late-apoptotic cells in Caco-2 cells with an 
increase range from 8.90% to 21.85%, while only 7-oxo-ganoderic acid Z and ganoderic 
acid DM are able to significantly (p < 0.05) stimulate mid-apoptotic cells in the same cell 
line with increase cell percentages of 5.48% and 11.68% respectively. Treatments of most 
of the compounds do not cause significant (p < 0.05) differences of percentage in dead 
cells except treatments of 7-oxo-ganoderic acid Z and 15-hydroxy-ganoderic acid S in 
Caco-2 cells which increase 3.5% and 5.3% respectively, and lucidumol A in HeLa cells 
which increases 7.95%. Among the six triterpenoids and the alcohol derivatives, 
ganoderic acid DM has the maximum reductions of viable cells and accumulations of 
late-apoptotic cells in both Caco-2 and HeLa cells. This triterpenoid also has the 
maximum cells accumulation in mid-apoptotic stage in Caco-2 cells compare to the other 
compounds but the cell percentage is less than that in late-apoptotic stage, indicating 
apoptosis induced by ganoderic acid DM is dominantly in late-apoptotic stage after 72 h 
treatment. Similar trends are shown in all treatments in Caco-2 cells and treatment of 
ganodermanontriol in HeLa cells. Conversely, ganolucidic acid E causes a maximum 
accumulation of mid-apoptotic cells and a minimum increase cell percentage in 
late-apoptotic stage in HeLa cells, suggesting apoptosis induced by ganolucidic acid E is 
dominantly in mid-apoptotic stage after 72 h treatment. Treatments of lucidumol A, 








Figure 18. Representative flow cytometry analysis of caspase activity of Caco-2 cells (A-E) 
and HeLa cells (F-J) treated with triterpenoids and the alcohol derivatives at their respective 
previously reported LC50 concentrations for 48 h. A, untreated control of Caco-2 cells; B, 
treatment of ganodermanontriol on Caco-2 cells; C, treatment of 7-oxo-ganoderic acid Z on 
Caco-2 cells; D, treatment of 15-hydroxy-ganoderic acid S on Caco-2 cells; E, treatment of 
ganoderic acid DM on Caco-2 cells; F, untreated control of HeLa cells; G, treatment of 
ganolucidic acid E on HeLa cells; H, treatment of lucidumol A on HeLa cells; I, treatment of 
ganodermanontriol on HeLa cells; J, treatment of 7-oxo-ganoderic acid Z on HeLa cells; K, 
treatment of 15-hydroxy-ganoderic acid S on HeLa cells; L, treatment of ganoderic acid DM 







Table 13. Quadrant analysis of apoptotic stages by flow cytometry in multi-caspase apoptotic 
assay. An asterisk represents a significant difference (p < 0.05) compared to the 
corresponding control values. 









Control 83.33 ± 0.81 5.39 ± 0.46 6.52 ± 0.14 4.64 ± 0.46 
Ganodermanontriol 72.82 ± 1.80* 5.471 ± 0.97 15.24 ± 2.01* 6.46 ± 0.21 
7-oxo-ganoderic acid Z 58.63 ± 1.11* 10.87 ± 0.66* 22.34 ± 0.49* 8.14 ± 0.85* 
15-hydroxy-ganoderic acid S 56.61 ± 2.84* 7.53 ± 0.61 25.92 ± 3.00* 9.94 ± 0.19* 
ganoderic acid DM 47.66 ± 1.16* 17.07 ± 0.75* 28.37 ± 0.90* 6.91 ± 0.76 
Treatments on HeLa cells     
Control 80.14 ± 1.10 10.34 ± 0.64 6.38 ± 054 3.03 ± 1.13 
ganolucidic acid E 48.68 ± 2.55* 36.63 ± 1.31* 10.94 ± 1.59* 3.75 ± 0.40 
lucidumol A 50.88 ± 1.38* 24.20 ± 0.30* 16.30 ± 0.80* 8.64 ± 0.69* 
Ganodermanontriol 43.99 ± 2.31* 25.81 ± 0.90* 28.42 ± 2.14* 2.55 ±0.81 
7-oxo-ganoderic acid Z 41.25 ± 0.64* 31.02 ± 2.63* 23.90 ± 1.75* 3.83 ± 0.42 
15-hydroxy-ganoderic acid S 42.36 ± 1.28* 30.37 ± 2.21* 23.98 ± 1.16* 3.30 ± 0.32 
ganoderic acid DM 39.36 ± 2.05* 17.09 ± 0.95* 40.74 ± 3.42* 2.79 ± 0.74 
 
7.3.2 Translocation of Phophatidylserine  
To determine the early apoptosis induced by Ganoderma lucidum triterpenoids and 
the alcohol derivatives in Caco-2 and HeLa cells, the translocations of phosphatidylserine 
were visualized by co-staining cells with annexin-V-FITC which specifically binds to 
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external cellular phosphatidylserine and PI which stains nuclear chromatin in cells 
without intact membranes. The results are shown in Figure 19. As negative controls, very 
little fluorescence signal is observed in Caco-2 and HeLa cells (Figure 19 A &F) without 
treatments. Conversely, green fluorescence from the annexin V-FITC conjugate is 
observed in all sample treatments, indicating all treatments are able to induce early 
apoptosis in Cao-2 and HeLa cells. It is also observed that this early apoptosis is 
dominant in treatments of 15-hydroxy-ganoderic acid S in Caoco-2 cells (Figure 19 D) 
and ganolucidic acid E, lucidumol A, ganodermanontriol, 15-hydroxy-ganoderic acid S 
and ganoderic acid DM in HeLa cells (Figure 19 G-I, K&L). Additionally, PI staining is 
observed to be positive for treatments of ganodermanontriol, 7-oxo-ganoderic acid Z and 
ganoderic acid DM in Caco-2 cells (Figure 19 B, C & E) and ganodermanontriol, 
7-oxo-ganoderic acid Z, 15-hydroxy-ganoderic acid S and ganoderic acid DM in HeLa 
cells (Figure 19 I-L), indicating these treatments also results in late apoptotic and dead 
cells. Changes of morphology in apoptotic cells and fragments of nuclear chromatin are 





Figure 19. Confocal images of cells co-stained with annexin V-FITC with green signal and PI 
with red signal. Representative apoptotic cells were identified by the blue arrow. A, untreated 
control of Caco-2 cells; B, treatment of ganodermanontriol on Caco-2 cells; C, treatment of 
7-oxo-ganoderic acid Z on Caco-2 cells; D, treatment of 15-hydroxy-ganoderic acid S on 
Caco-2 cells; E, treatment of ganoderic acid DM on Caco-2 cells; F, untreated control of 
HeLa cells; G, treatment of ganolucidic acid E on HeLa cells; H, treatment of lucidumol A on 
HeLa cells; I, treatment of ganodermanontriol on HeLa cells; J, treatment of 7-oxo-ganoderic 
acid Z on HeLa cells; K, treatment of 15-hydroxy-ganoderic acid S on HeLa cells; L, 
treatment of ganoderic acid DM on HeLa cells. 
7.3.3 Observation of Cytochrome-c Reselase from Mitochondria  
The visualizations of co-localization of cytochrome c and mitochondria and the 
release of cytochrome c by confocal microscope are shown in Figure 20. Cytochrome c 
in cells with treatments of all triterpenoids and alcohol derivatives are partially released 
into the cytosol from mitochondria in both Caco-2 and HeLa cells, which is evident by 
relatively strong green fluorescence from Anti-Cytochrome C FITC, compared to the 
co-localizations of cytochrome c and mitochondria in untreated control cells, which 







Figure 20. Release of cytochrome c from mitochondria in response of apoptosis visualized by 
confocal fluorescence microscopy. Co-localization of cytochrome c in green signal and 
mitochondria in red signal were shown in A, untreated control of Caco-2 cells; B, treatment of 
ganodermanontriol on Caco-2 cells; C, treatment of 7-oxo-ganoderic acid Z on Caco-2 cells; 
D, treatment of 15-hydroxy-ganoderic acid S on Caco-2 cells; E, treatment of ganoderic acid 
DM on Caco-2 cells; F, untreated control of HeLa cells; G, treatment of ganolucidic acid E 
on HeLa cells; H, treatment of lucidumol A on HeLa cells; I, treatment of ganodermanontriol 
on HeLa cells; J, treatment of 7-oxo-ganoderic acid Z on HeLa cells; K, treatment of 
15-hydroxy-ganoderic acid S on HeLa cells; L, treatment of ganoderic acid DM on HeLa 
cells. Representative cytochrome c releases were shown by the white arrow. 
 
7.3.4 Signaling pathways involved in apoptosis induction  
To determine possible pathways involved in the cellular regulation mediated by 
Ganoderma lucidum triterpenoids and the alcohol derivatives, six triterpenoids and 
alcohol derivatives, which were all able to induced apoptosis in HeLa cells, were tested 
using luciferase reporter arrays. Comparably, two of these triterpenoids exhibiting 
cytotoxicity but not inducing apoptosis, were also tested in Hep G2 cells as they 
represented the two major cell cycle arrest induction (S and G2/M) in Hep G2 as reported 
in chapter 6. The fold change of relative luciferase units compared to untreated controls 
of each pathway are summarized in Figure 21. Treatment of ganolucidic acid E results in 
significant (p < 0.05) up regulations of the reporter activity in Notch (RBP-Jκ reporter) 
(3.50 fold) and p53 pathways (2.08 fold) and down regulation of reporter activity in 
transforming growth factor beta (TGFβ, SMAD reporter) (0.73 fold), NFκB (0.20 fold), 
c-myc (myc reporter) (0.54 fold) and hypoxia (HIF reporter) pathways (0.53 fold) in 
HeLa cells. Treatments of lucidumol A causes significant (p < 0.05) increased 
associated-luciferase activity in p53 reporter (3.03 fold) and E2F reporter (cell cycle 
regulation pathway, 5.68 fold) while reduced the activity of NFκB (0.56 fold), myc (0.74 
fold), HIF (0.49 fold), serum response element (SRE, MAPK/ERK pathway) (0.58 fold) 
and AP-1(MAPK/JNK pathway) (0.49 fold) reporters in HeLa cells. HeLa cells exposed 
to 7-oxo-ganoderic acid Z also results in significant (p < 0.05) up regulations of reporter 
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activity of RBP-Jκ (2.74 fold), p53 (2.62 fold) and E2F (2.26 fold) and down regulations 
of reporter activity of NFκB (0.75 fold) and HIF (0.78 fold). Exposure of the same cell 
line to 15-hydroxy-ganoderic acid S significantly (p < 0.05) up-regulates the activity of 
p53 (1.84 fold) and E2F reporter (1.80 fold) and down-regulates reporter activity of 
SMAD (0.33 fold), NFκB (0.66 fold) and myc (0.77 fold). Treatment of ganoderic acid 
DM causes similar up regulations in p53 (3.84 fold) and cell cycle signaling (2.83 fold) 
while it resulted in reduced activity of NFκB (0.75 fold), myc (0.73 fold) and HIF 
reporter (0.47 fold) in the same cell line. While treatment of ganodermanontriol did not 
result in any signaling up-regulation, instead the treatments significantly (p < 0.05) 
down-regulates the reporter activity of SMAD (0.43 fold) and NFκB (0.50 fold) in HeLa 
cells. Compared to treatments in HeLa cells, exposure of Hep G2 cells to the treatments 
of 15-hydroxy-ganoderic acid S resulted in significant (p < 0.05) up regulations in SMAD 
and E2F reporter activity with 2.87 and 2.45 fold respectively, while the reporter activity 
of Tcf/Lef (Wnt pathway), myc and AP-1 was significantly decreased by 0.69, 0.53 and 
0.71 folds respectively. Treatments of ganoderic acid DM results in significant (p < 0.05) 
up regulations in reporter activity of RBP-Jκ (1.94 fold) and SMAD (2.81 fold) and down 
regulations in reporter activity of Tcf/Lef (0.75 fold) myc (0.53 fold) and HIF (0.42 fold). 
Neither of the treatments cause significant (p < 0.05) changes in p53, NFκB and SRE 





Figure 21. Signaling pathways in response to treatments of Ganoderma lucidum triterpenoids and alcohol derivatives in HeLa (upper panel) and Hep G2 
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7.4 Discussions  
In chapter 6 we has reported that six triterpenoids and the alcohol derivatives 
induced apoptotic cell death and DNA fragmentation in HeLa cells and four of them had 
similar effects on Caco-2 cells by TUNEL assay. This chapter focuses on the possible 
mechanism of apoptotic cell deaths. The apoptotic cell deaths resulted from the six 
triterpenoids and alcohol derivatives were evidenced by the positive staining of 
multi-caspase activities using the fluorochrome conjugated caspase inhibitor of caspase 3, 
7, 8 and 9 in Caco-2 and HeLa cell. Hep-G2 cell line was not used as we previously 
reported no induction of apoptosis after treatments in chapter 6. The percentages of cells 
at mid-apoptotic and late-apoptotic stages varied with respect to different sample 
treatments and cell lines in the multi-caspase apoptotic assay, which indicated that the 
apoptotic cell deaths induced by Ganoderma lucidum triterpenoids and the alcohol 
derivatives might be cell specific. However, no obvious structure-activity relationships 
regarding to this variations was observed. The implication of caspase-dependent 
apoptosis induced by Ganoderma lucidum triterpenoids and the alcohol derivatives were 
consistent with reported caspase activation of ganoderic acids in other carcinoma cells. 
For instant, caspase-3 but not caspase-8 was found to be stimulated during apoptosis 
induced by ganoderic acid T in 95-D cells [169]. Activation of caspase 3 was also 
observed in the apoptotic process with treatment of ganoderic acid Me in HCT-116 cells 
while caspase 3 and 9 were activated during apoptosis resulted from treatment of 
ganoderic acid Mf and S in HeLa cells [49;50]. However, the conclusion that Ganoderma 
lucidum triterpenoids and their derivatives induced apoptosis through activation of the 




It is well accepted that the apoptotic cell deaths are usually associated with 
externalization of phosphatidylserine from the inner leaflet of the plasma membrane into 
outer leaflet, which results from activation of calcium-dependent scramblase and 
inhibition of aminophospholipid translocase triggered by released cytochrome c from 
mitochondria [172]. The exposed phosphatidylserine in the surface of apoptotic cells 
subsequently signal the phagocytosis by recruiting specialized receptors of phagocytes for 
removal of apoptotic cells [173]. Detection of the externalization of phosphatidylserine 
and early stage of apoptosis are usually done by utilizing the fluorescent conjugate of 
Annexin V which exhibits strong and natural affinity to phosphatidylserine [174]. In this 
chapter, all six triterpenoids and alcohol derivatives showed positive results for 
phosphatidylserine externalization in HeLa cells and four in Caco-2 cells with various 
extents of annexin V-FITC and PI staining, indicating effects of triterpenoids and the 
alcohol derivatives also vary in the induction of the early stage of apoptosis. Results from 
the annexin V/PI apoptotic assay were consistent with the reported findings of treatments 
of ganoderic acid Me in HCT-116 cells, with more than 20% annexin V-positive 
apoptotic cells at 90.4 µM for 24 h treatment, and treatments of ganoderic acid Mf and S 
in HeLa cells at concentrations up to 97.7 µM, with a dose-dependent increase of early 
and late apoptotic cells [49;50]. 
Related to phosphatidylserine externalization, release of cytochrome c from 
mitochondria plays an important role in regulating apoptotic cell death. On one hand, 
cytochrome c released from mitochondria is thought to mediate oxidation of 
phosphatidylserine that subsequently interacts with aminophospholipid translocase and 
causes phosphatidylserine externalization [175]. On the other hand, the released 
cytochrome c can interact with apoptotic protease activating factor 1(Apaf1) and 
subsequent recruit caspase-9 forming apoptosomes [176]. In this chapter, the releases of 
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cytochrome c from mitochondria were observed in all sample treatments in Caco-2 and 
HeLa cells as expected, which further confirmed and supported the involvement of 
caspase activation and phosphatidylserine externalization during apoptosis induced by 
triterpenoids and the alcohol derivatives. The releases of cytochrome c were also 
consistent with reported observations in different cell lines with treatments of other 
Ganoderma lucidum triterpenoids, which include ganoderic acid T in 95-D cells with 
3-fold increase in the cytochrome c level for 8 h treatment, ganoderic acid Mf and S in 
HeLa cells with up to 5.81-fold increase cytochrome c at a concentration of 97.7 µM and 
ganoderic acid Me in HCT-116 cells with 3-fold increase in the cytochrome c level for 12 
h treatment at a concentration of 90.4 µM [49;50;169].  
Multiple changes were observed in the luciferase reporter array after treatments with 
Ganoderma lucidum triterpenoids and the alcohol derivatives in both HeLa (apoptotic 
positive) and Hep G2 (apoptotic negative). Exposure of Hep G2 cells to 
15-hydroxy-ganoderic acid S and ganoderic acid DM resulted in a significant decrease in 
the Wnt pathway reporter Tcf/Lef-associated luciferase activity while the activity of 
Tcf/Lef was not influenced by any of the treatments in HeLa cells. Aberrant activation of 
Wnt-signaling, which involves stabilization and accumulation of β-catenin that interact 
with Tcf/Lef to initiate transcription of proliferation stimulating genes such as c-myc and 
cyclin D1, has been reported to closely related to the progression of human cancers 
including colorectal cancer and hepatocellular carcinoma [177]. Inhibition of 
Wnt-signaling was found to inhibit cell growth and induce apoptosis in carcinoma cells 
[69;178]. In particular, the Ganoderma lucidum alcohol, ganodermanontriol has been 
reported to inhibit transcription activity of β-catenin, down-regulate cyclin D1 and inhibit 
cell growth in HT-29 colon carcinoma cells, which indicated an involvement of 
Wnt-signaling [69]. However, ganodermanotriol did not participate in the Wnt-signaling 
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in HeLa cells based on our analysis, indicating the Wnt-signaling regulation may be cell 
specific and the detailed regulation of the Wnt family proteins may need further 
exploration. 
  The luciferase reporter array indicated that the associated-luciferase activity of the 
Notch reporter, RBP-Jκ (also known as C protein binding factor 1/Suppressor of 
Hairless/Lag1 (CBF1/ Su (H)/Lag 1)), was significantly up-regulated by ganolucidic acid 
E and 7-oxo-ganoderic acid Z in HeLa cells, and ganoderic acid DM in Hep G2 cells. The 
Notch pathway has been implicated in mammary carcinogenesis but its role in 
carcinogenesis was reported to be controversial and probably to be highly cell and context 
specific. This is likely due to the complex interplay of four receptors (Notch1, Notch 2, 
Notch 3 and Notch4) and five ligands (Jagged1, Jagged2, Delta-like ligand 1, ligand 3, 
and ligand 4) in this signaling and the crosstalk of Notch signaling with NF-κB, Akt and 
P53 signaling [179-183]. Detailed examinations of the activity in four receptors are 
required to elucidate impacts of Ganoderma lucidum triterpenoids and the alcohol 
derivatives on Notch signaling in the two cell lines in the future. 
As the well accepted tumor-suppressor gene, the associated-luciferase activity of p53 
was observed to significantly increase in the treatments of ganolucidic acid E, lucidumol 
A, 7-oxo-ganoderic acid Z, 15-hydroxy-ganoderic acid S and ganoderic acid DM in HeLa 
cells but not with treatments of ganodermanontriol in HeLa cells or 15-hydroxy-ganodric 
acid S and ganoderic acid DM in Hep G2 cells. The increased p53 reporter activity 
reported in this chapter is consistent with data in the previous chapter (chapter 6), which 
showed significant increase in DNA fragmentation in TUNEL assay in Caco-2 and Hela 
cells. In the previous chapter (chapter 6), however, the cell percentage with DNA 
fragmentation of ganodermanontriol treatment in HeLa cells had a minor increase though 
it had statistical differences compared to control cells and concomitantly, the p53 reporter 
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activity was not activated by ganodermanontriol in this chapter. Similarly, the inability to 
stimulate p53 reporter activity in Hep G2 cells is consistent with the negative results of 
zero sub-G1 accumulation in cell cycle analysis in chapter 6. The results in this chapter 
are also consistent with the up-regulation of p53 expression as reported in the treatments 
of ganoderic acid Me in multidrug resistant clone cancer cells and HCT-116 cells and 
ganoderic acid T in 95-D cells [49;169;184]. 
The TGF β signaling has been suggested biphasic stage-specific effects in carcinoma 
development. On one hand, down regulation and inactivation of TGF β receptors and 
SMADs have been implicated in the development of various human cancers. Therefore, 
TGF β served as tumor suppressor in epithelial cell growth by inducing apoptosis and 
modulating cell cycle regulators in the stage of carcinoma initiation [185;186]. On the 
other hand, high level expression of TGF β was found to be associated with progressive 
cell proliferation, invasion and metastasis in the advanced staged of established tumors 
[187;188]. Ganoderma lucidum has been reported to inhibits prostate cancer-dependent 
angiogenesis with decreased secretion of vascular endothelial growth factor and TGF β1 
from PC-3 highly invasive human prostate cancer cells [189]. Consistent with this report, 
exposure of ganolucidic acid E, ganodermanontriol and 15-hydroxy-ganoderic acid S to 
HeLa cells resulted in a significant reduction in the associated luciferase activity of TGF 
β reporter SMAD. Conversely, significant activation of SMAD was observed in 
treatments of 15-hydroxy-ganoderic acid S and ganoderic acid DM in Hep G2 cells. 
Results suggested that TGF β may regulate differently in response to Ganoderma lucidum 
triterpenoids and the alcohol derivatives mediated- cell growth inhibition in HeLa and 
Hep G2 cells. 
In chapter 6, cell cycle arrest has been observed in Ganoderma lucidum triterpenoids 
and the alcohol treatments in Caco-2, HeLa and Hep G2 cells. In this study, the associated 
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luciferase activity of E2F which is a reporter related to cell cycle progression, was 
observed to significantly increase in the treatments of lucidumol A, 7-oxo-ganoderic acid 
Z, 15-hydroxy-ganoderic acid S and ganoderic acid DM in HeLa cells and 
15-hydroxy-ganoderic acid S in Hep G2 cells. Conversely, exposure of HeLa cells to 
ganolucidic acid E, lucidumol A, 15-hydroxy-ganoderic acid S and ganoderic acid DM 
and exposure of Hep G2 cells to 15-hydroxy-ganoderic acid S and ganoderic acid DM all 
resulted in significant reduction in the associated-luciferase activity of myc, which was 
another reporter related to cell cycle progression. Similar results have been reported that 
increased expression of E2F correlated to suppression of cell proliferation in HeLa and 
Hep G2 cells [190;191]. Our findings were also consistent with the reports that down 
regulation of myc were associated with cell proliferation inhibition and apoptosis 
inductions in HeLa and Hep G2 cells [66;192]. However, the E2F and myc families of 
transcription factors both have been reported to possess the dual functions in transactivate 
and repress gene expression that regulate DNA replication, mitosis, DNA-damage and 
repair, apoptosis and differentiation [193-195]. It is likely that these two reporters mediate 
the Ganoderma lucidum triterpenoids and the alcohol derivatives induced-cell cycle arrest 
and apoptosis independently or through interacting with other transcription factors such 
as SMADs and Tcf/Lef, which need further investigations on their upstream and 
downstream signaling.   
Apart from induction of cell cycle arrest and apoptosis, Ganoderma lucidum extract 
and its triterpenoids have been reported to inhibit metastasis and invasion in MCF-7 and 
Hep G2 cells through inhibition of phosphorylation of ERK1/2 and reducing AP-1 and 
NF-κB [196;197]. Consistent with these reporting signaling, the associated luciferase 
activity of NF-κB was found to be significantly decreased with treatments of all six 
triterpenoids and the alcohol derivatives in HeLa cell, while its activity in Hep G2 cells 
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were not affected. Activity of AP-1 was significantly reduced with exposure to lucidumol 
A in HeLa cells and 15-hydroxy-ganoderic acid S in Hep G2 cells. The activity of SRE, 
which is the ERK1/2 reporter, was observed to significantly decrease with exposure to 
lucidumol A in HeLa cells. Reduced level of these reporters may play a role in the 
inhibition of transactivation of cyclin D1, Bcl-2, COX-2 and activation of p16, p21 and 
p53, which closely regulate cell cycle progression, cell proliferation, invasion and 
metastasis [198-201]. 
In this chapter, we also found that the associated-luciferase activity of HIF, the key 
transcription factor of hypoxia, was significantly reduced by treatments of ganolucidic 
acid E, lucidumol A, 7-oxo-ganoderic acid Z and ganoderic acid DM in HeLa cells and 
ganoderic acid in Hep G2 cells. Hypoxia has been reported to trigger tumor angiogenesis 
and correlate positively to tumor malignant progression, chemoradio-resistance and poor 
prognosis. Studies have indicated that activation of HIF was responsible for a number of 
oncogenic signaling activation and tumor suppressors inactivation [202;203]. This is the 
first report indicating that suppression of HIF might be associated with the regulation of 
cell proliferation and apoptosis mediated by Ganoderma lucidum triterpenoids and the 
alcohol derivatives in HeLa and Hep G2 cell. 
Taken together, the apoptotic cell deaths triggered by treatments of Ganoderma 
lucidum triterpenoids and the alcohol derivatives were associated with caspase activation, 
phosphatidylserine externalization and cytochrome c release. The apoptosis was also 
suggested to involve multiple signaling mechanisms in HeLa cells. However, it is not yet 
clear which signaling would be the direct targets of these triterpenoids and the alcohol 
derivatives and whether indirect signaling regulations could be involved. Further 




CHAPTER 8 OVERALL CONCLUSIONS AND FUTURE STUDY 
In this thesis, the chemical characterizations of bioactive components of Ganoderma 
lucidum have been conducted and methods were developed to isolate and identify 
Ganoderma lucidum lipids and triterpenoids and their derivatives. Ganoderma lucidum 
lipids were found to consist of long chain fatty acids, hydroxyl fatty acids and possibly 
sterol derivatives and phospholipids while the exact structures of some lipid components 
remained unknown (Chapter 4). Further isolation and identification of these components 
are required in the future. In addition to Ganoderma lucidum lipids, a total of 21 
triterpenoids and derivatives have been identified in Ganoderma lucidum and 13 of them 
have been isolated as pure compounds from two triterpenoid enriched extracts (Chapter 3, 
5 and 6). Extraction conditions such as extraction time and the ratio of organic solvents 
were found to significantly influence the extraction yield of triterpenoids and optimal 
extraction conditions of certain triterpenoid have been developed using a quadratic model 
(Chapter 5). Future work should be centered on triterpenoids and their derivatives that 
have not been adequately identified and isolated from Ganoderma lucidum. 
 On the other hand, Ganoderma lucidum lipids and triterpenoids and their 
derivatives have been well documented in this thesis to possess possible 
chemo-preventative properties with diverse bioactive effects on three cultured human 
carcinoma cells. Initial observations have showed that two triterpenoids fractions 
(fraction 2 and 3) separated from an ethanol extract of Ganoderma lucidum were able to 
reduce the Caoc-2 cell viability dose dependently and cause a cell cycle arrest in G2/M 
phase, but only one of them (fraction 3) induced apoptotic cell death in Caco-2. The 
results indicated that variation in polarity of triterpenoids in these extracts may 
specifically influence the cyto-response in the cells (Chapter 3).  
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The subsequent investigations have extended the initial understating to the 
bioactivity of 13 triterpenoids and the alcohol derivatives in Caco-2, HeLa and Hep G2 
cells. An implication of potential structure-activity relationships have been established 
that triterpenoids without functional group at C-23 position and less saturation of the side 
chain could result in greater cytotoxicity in carcinoma cells (Chapter 3, 5 and 6). 
Moreover, the effects of 6 cytotoxic triterpenoids and the alcohol derivatives in three cell 
lines were shown to be cell-specific and dependent on structure, which is evident by the 
variation of cytotoxicity and cell cycle arrest at G1, S and G2/M phase induced by 
different compound treatments in Caco-2, HeLa and Hep G2 cells (Chapter 6). The 
apoptosis response also varied with respect to the six triterpenoids and alcohol derivatives, 
all of which had different extents of sub-G1 accumulation and positive staining in 
TUNEL assay in HeLa cells and four in Caco-2 cells but none in Hep G2 cells (Chapter 
6).  
The apoptotic cell death induced by cytotoxic triterpenoids and the alcohol 
derivatives in Caco-2 and HeLa cells were associated with caspase activations, 
phosphatidylserine externalization and cytochrome c release as detected by multi-caspase 
apoptotic assay, annexin-V-FITC/PI staining and anti-cytochrome c-FITC staining 
respectively (Chapter 7). A screening of possible pathways for apoptosis regulation 
suggested that multiple signaling pathways could be involved in the triterpenoids and 
alcohol derivatives mediated-apoptosis in HeLa cells, most of which include transcription 
activation of p53 and E2F and down regulation of NFκB, Myc and HIF (Chapter 7). Since 
some of signaling could crosstalk and interact with one another, future studies should 
centre on the upstream and downstream signaling of each pathway. Elucidation of the 
direct target of these signaling regulations would aid in understanding of the 
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structure-activity relationship of Ganoderma lucidum triterpenoids and the derivatives as 
apoptosis inducer in chemotherapy.  
The bioactivities of a lipid enriched fraction and its ethanol crude extract of 
Ganoderma lucidum were also conducted in Caco-2 cells. The ethanol crude extract 
which contained triterpenoids besides lipids were found to be cytotoxic to Caco-2 cells as 
expected but its cytotoxicity rapidly declined after cells reaching confluency. Unlike 
triterpenoids from Ganoderma lucidum, the lipid enriched extract did not exhibit 
cytotoxicity to Caco-2 cells. Neither of these extracts induced apoptosis in Caco-2 cells 
but instead, they induced differentiation in Caco-2 cells with significant stimulation of 
alkaline phosphates and lactase activity (Chapter 4). Further analysis indicated that the 
differentiation induced was associated with a G2/M cell cycle arrest and possibly 
mediated through activation of JNK and ERK pathways and an indirect activation of PKC 
(Chapter 4). Future study is needed to examine the involved pathway signaling at 
posttranscriptional level is proposed to elucidate the exact underlying mechanisms. 
Nevertheless, the capability of Ganoderma lucidum lipids to induce differentiation in 
colonic cells give it potential as therapeutic agents for restoring carcinoma cells into 
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APPENDIX 2  
Cell viability of fraction1 treated Caco-2 cells for 72h and assessed using the MTT assay. 
Values are expressed as mean ± SD (percentage of untreated control cells) of three 




























Effects of repeated extractions on extraction efficiency of Ganoderma lucidum 
triterpenoids. Values are expressed as mean ± SD (mg lyophilized powder of extract/g 
Ganoderma lucidum powder) of three replicate experiments. Reflux extraction were 











































































APPENDIX 4  









APPENDIX 5  
13C and DEPT 13C NMR spectrum of identified triterpenoids and alcohol derivaties from Ganoderma lucidum in this study 
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